Understanding hairy cell leukemia in the context of mature B−cell neoplasms: tumor microenvironment and extracellular vesicle contribution to disease pathogenesis

Abstract

Mature B-cell neoplasms constitute a biologically and clinically heterogeneous group of hematologic malignancies, defined by the clonal proliferation and accumulation of monotypic mature B lymphocytes, which may involve the peripheral blood, bone marrow (BM), lymphoid tissues, or present primarily in extranodal sites. While the pathogenesis of common subtypes, such as chronic lymphocytic leukemia, multiple myeloma, Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma has been extensively studied, those of rare entities like Hairy Cell Leukemia (HCL) remains poorly understood. HCL is a distinct B-cell neoplasm marked by BM infiltration of atypical “hairy” cells, pancytopenia, BM fibrosis, and the BRAF V600E mutation, which is a defining molecular hallmark of the classic form of the disease. Analogous to solid tumors, growing evidence shows that the tumor microenvironment (TME) is a pivotal contributor in both the initiation and progression of all these malignancies. However, in rare mature B-cell neoplasms, understanding how tumor cells interact with their microenvironment, in terms of immune invasion, stromal crosstalk, and tissue remodeling, remains a challenge, partly due to the scarcity of patient samples and limited availability of preclinical models. In the context of TME, extracellular vesicles (EVs) have emerged as central mediators of intercellular communication within both solid and hematological malignancies. In line with numerous findings from solid tumors, EVs are receiving heightened attention as key mediators of disease progression, immune modulation, and treatment response in blood tumors, by modulating cellular interactions and delivering bioactive cargo in the tumor milieu. This review presents HCL within the broader spectrum of mature B-cell neoplasms, highlighting the current state of knowledge on the dynamic crosstalk between malignant B cells and their TME. Particular attention is given to EVs, which play key immuno-regulatory roles by interacting with both immune and non-immune components of the TME, including stromal cells. We explore how EVs contribute to disease pathogenesis, offering a unifying framework for integrating complex interactions that are often under-investigated in rare disease contexts. Building on this synthesis, we propose that the insights gained from well-characterized lymphoproliferative disorders may serve as a valuable foundation for investigating related yet poorly understood conditions, such as HCL. Furthermore, given the scarcity of both biological samples and reliable preclinical models for rare hematological malignancies, we highlight the strategic role of European biobanks in providing access to well-annotated clinical samples—an essential resource for fostering interdisciplinary collaboration and enabling advanced experimental modelling.

1 Epidemiological trends and classification of mature B-cell neoplasms

Mature B-cell neoplasms constitute a biologically and clinically heterogeneous group of hematologic malignancies, defined by the clonal proliferation and accumulation of monotypic mature B lymphocytes which may involve the peripheral blood, bone marrow (BM), lymphoid tissues or present primarily in extranodal sites. They encompass diverse entities differing in morphology, immunophenotype, clinical behavior, and genomic features. For epidemiologic purposes, they are usually grouped into Non-Hodgkin lymphomas (NHL), Hodgkin lymphoma (HL), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM), although each category includes multiple distinct subtypes (1).

Lymphomas commonly arise in lymph nodes (which appear enlarged in most instances); however, they may also involve primarily extranodal sites—such as the gastrointestinal tract or central nervous system, often with secondary BM infiltration (2–4). Mature B-cell leukemias and plasma cell neoplasms involve the BM in almost all cases (with an exception represented by extraosseous plasmacytoma). CLL, indeed, is by definition characterized by circulating mature neoplastic B-lymphocytes, which in turn re-circulate between marrow and lymph nodes (where the initial neoplastic events take place), and again between marrow and peripheral blood (5). Certain mature B-cell neoplasms recognized in the WHO-HAEM5 classification—such as splenic marginal zone lymphoma and related entities—are characterized by predominant splenic involvement as a defining feature and often accompanied by marrow infiltration and usually lacking significant lymph node enlargement. Hairy cell leukemia (HCL), for example, displays infiltration of splenic red pulp, hepatic sinusoids and portal tracts together with a low circulating leukemic burden (6). Lastly, MM is characterized by skeletal lytic lesion, resulting from increased bone resorption due to dysregulated bone remodeling driven by the complex crosstalk among neoplastic plasma cells, BM stromal cells, osteoclasts, and osteoblasts (7).

Classification systems have evolved substantially (8–13). The REAL classification (1994) introduced a multidimensional diagnostic model incorporating morphology, immunophenotype, clinical data, and genetics. This framework was expanded by WHO classifications in 2001, 2008, and 2017 (11–13). Advances in genomics led to the 2021 International Consensus Classification and the 2022 WHO-HAEM5, reflecting updated molecular knowledge and clinical insights (14, 15). Clinical context—age, disease distribution, exposure history, organ involvement, and blood counts—remains essential for accurate diagnosis (15).

Epidemiological data (GLOBOCAN) show rising global incidence and mortality of B-cell malignancies, underscoring the need for continued research (14, 16, 17). Although rare entities such as HCL are not specifically reported, HCL accounts for ~2% of leukemias and ~1% of lymphoid neoplasms, with an incidence of 0.3/100,000 per year (18, 19). Classic HCL is an indolent but incurable B-cell malignancy affecting predominantly middle-aged to older men (20, 21). Its rarity underscores the need for tailored approaches within low-incidence subgroups.

2 From germinal centers to malignancy: the cellular and molecular basis of mature B-cell neoplasms

Clonal expansion of B-cells and antibody affinity maturation occur within germinal centers (GCs), which form in B-cell follicles of secondary lymphoid organs after antigen stimulation. Naïve B-cells receiving follicular helper T-cell (Tfh) support, migrate into follicles where they initiate GC formation (22).

Within the GC, B cells proliferate rapidly and undergo somatic hypermutation of immunoglobulin variable genes. Mutated clones are selected through interactions with follicular dendritic cells and Tfh cells, allowing only higher-affinity B-cell receptor variants to survive (23, 24). The WHO classification organizes mature B-cells neoplasms into 12 families (25) reflecting their GC or non-GC origin (15). Malignant transformation from a normal B-cell to a malignant clone is driven by a combination of chromosomal aberrations, somatic mutations, and epigenetic dysregulation, which disrupt physiological checkpoints of maturation and immune regulation.

CLL exemplifies this heterogeneity: mutated IgHV (M CLL) reflects post-GC memory B cell origin and indolent behavior (5, 16, 26–28), whereas unmutated IgHV (U CLL) derives from naïve pre-GC B cells and is associated with aggressive disease (29). Cytogenetic lesions—including del(13q14), del(11q22 23), trisomy 12, and del(17p12)—further guide prognosis and therapy, with trisomy 12 and del(17p12) being more frequent in U CLL than in post-GC M CLL (5, 30). Post-GC neoplasms include also HL (both classic HL and nodular lymphocyte-predominant HL), Diffuse large B-cell lymphomas (DLBCLs), Primary mediastinal large B-cell lymphoma (PMBCL), non-nodal Mantle cell lymphoma (nnMCL), MM and HCL. Gene-expression profiling identifies two DLBCL subtypes. Activated B-cell-like (ABC), a post-GC aggressive form driven by chronic active BCR signaling and NF-κB–activating mutations (TNFAIP3, MYD88, CD79A/B, CARD11), and Germinal Center B-cell–like (GCB), linked to lesions such as t (14, 18) and mutations in epigenetic regulators like CREBBP and EZH2 (31). Indeed, GCB subtype cells present more specific mutations related to lymphomagenesis, such as t (14, 18)(q32;q21) translocation that activates BCL2 promoting survival, and mutations affecting epigenetic regulation (CREBBP, EZH2) (31). MCL subtyping shows nnMCL as a post-GC, indolent, IGHV-mutated, SOX11-negative entity, differentiating it from the conventional aggressive (cMCL) (32). A defining molecular feature of almost all classic HCL cases is the BRAFV600E mutation, found in virtually all patients with very few exceptions. This mutation plays a central role in disease pathogenesis by activating the RAF-MEK-ERK signaling pathway, which drives uncontrolled proliferation and enhances survival of the malignant hairy cells (33).

HCL is unique among all hematologic malignancies due to several peculiar morphologic, immunophenotypic, molecular, and clinical features with not only initial sensitivity to myelotoxic chemotherapy with purine analogs, but also frequent relapses accompanied by a progressive loss of response to these drugs with time, calling for new therapeutic strategies. The near-universal BRAFV600E mutation activates the RAF-MEK-ERK signaling, which, in turn, drives uncontrolled proliferation and enhances survival of the malignant hairy cells. AKT–mTOR alterations also hold significance as a prognostic marker in patients with HCL (33, 34). Although several new drugs (BRAF/MEK inhibitors, and anti-CD22 immunotoxin) have been explored, purine analogs remain the standard of care for these patients, mostly as frontline therapy. These agents induce durable and unmaintained complete response in more than 70% of patients, and the relapse rates are about 30% to 40% after 5 to 10 years of follow-up, with overall survival frequently longer than 20 years. The HCL-variant (HCL-V), recently renamed in the WHO-HAEM5 classification as “Splenic B-cell lymphoma/leukemia with prominent nucleoli” (15), differs biologically and is more treatment-resistant (35). Due to these peculiarities, this will not be discussed in the present review.

GC-derived neoplasms include Burkitt Lymphoma (BL), Follicular Lymphoma (FL), and GCB-DLBCL which frequently carry hallmark translocations—t (8, 14) in BL, t (11, 14) in MCL, and t (14, 18) in FL (36, 37). Additional copy number alterations (CNAs), single nucleotide variants (SNVs), and structural variants (SVs) involving TP53, MYC, BCL2, EZH2, and KMT2D further promote the malignant transformation (38). In light of this molecular heterogeneity, it is worth to highlight that advances in next generation sequencing (NGS), whole-exome sequencing (WES), RNA-seq, and circulating tumor DNA (ctDNA) analysis have transformed diagnosis and monitoring across B-cell malignancies (39).

Understanding cellular origin and molecular drivers remains essential for accurate classification and targeted management. The “cryptic” nature of HCL reflects its fully mature yet aberrant B-cell phenotype, which diverges from normal maturation pathways (40).

2.1 Immunophenotyping in mature B-cell tumor diagnostics

The diagnosis of B-cell neoplasms relies on integrating clinical features, morphology, molecular testing, and immunophenotyping, which together determine lineage and maturation stage (41). Multiple diagnostic techniques support this process (42). Immunohistochemistry (IHC) on lymph node or BM biopsies, provides diagnostic prognostic and predictive insights including eligibility for target therapies, such anti- Programmed Death-Ligand (PD-L)1, CD19, CD20 or CD30 therapies (43). Flow cytometry further refines classification by analyzing antigen expression at the single-cell level (44).

Mature malignant B-cells generally lack antigenic determinants characteristic of immature B-cell phenotypes, such as TdT and CD34, while expressing CD19, CD20, and CD22 (45). Distinctive immunophenotypes support differential diagnosis across entities (46–56).

HCL is characterized by clonal expansion of mature B-cells arrested at a late stage of differentiation, showing a strong light chain restricted immunoglobulin with bright expression of CD19, CD20, CD22 and CD200. Interestingly, HCs are usually negative for CD5, CD23, CD10, and CD27 and positive for CD11c, CD103, CD123, and CD25. Strong positivity for C-C Motif Chemokine Receptor (CCR)3, CCR6, C-X-C chemokine receptor type 4 (CXCR4), CD26, PD-1 and Annexin A1 is also observed. A strong dependence of hairy cells on extracellular stimuli has been described including interactions with BM stromal cells and matrix. However, the mechanisms governing these interactions are still unknown. Preliminary observations suggest that CD11c and CD103 promote stromal interactions and marrow retention (21, 48, 57, 58).

Adhesion molecules further influence disease behavior. In CLL, the integrins LFA-1(CD11a/CD18) and VLA-4 (CD49d/CD29)—especially in trisomy 12—enhance ICAM-1 and vascular cell adhesion molecule 1 (VCAM-1) binding and correlate with aggressiveness. In MM, LFA-1, VLA-4, CD44, and ICAM-1 mediate BM adhesion and drug resistance (59).

Figure 1 resumes what we have pointed out on morphology, immunophenotype and genetic landscape of mature B-cell neoplasms.

Figure 1

2.2 Clinical features

Lymph node enlargement is the hallmark of lymphoproliferative disorders. Rapidly growing, asymmetric lymphadenopathy is typical of aggressive lymphomas such as DLBCL, BL and cMCL. HL characteristically presents supradiaphragmatic nodal disease, most frequently involving the mediastinum. The mediastinum represents the predominant or exclusive site of disease in PMBCL, often presenting as a bulky mass (>10 cm) with compression of thoracic structures. Indolent lymphomas such as FL and CLL usually show disseminated, symmetric lymphadenopathy with slow growth, although bulky abdominal or retroperitoneal masses may occur. BM involvement is frequent in indolent lymphomas but uncommon in aggressive subtypes; however, clinically significant BM failure with cytopenia occurs only in advanced disease and represents an indication for treatment. Extranodal involvement may be observed in all lymphoma subtypes. In DLBCL and BL it is usually synchronous with nodal disease and may cause organ dysfunction, whereas post-germinal center indolent lymphomas may even arise from the mucosa-associated lymphoid tissue of the gastrointestinal tract, the airways or the skin, without spreading to nodes, in these cases being defined as “primary extranodal”. Lymphocytosis is typical of CLL, though leukemic phases may occur in other NHLs, most commonly non-nodal MCL, especially in the most advanced phases. Splenomegaly is frequent in CLL and indolent lymphomas but rare in aggressive forms. MM is presented uniquely with BM plasma cell infiltration causing anemia, bone disease and hypercalcemia, and with a monoclonal protein leading to renal dysfunction or hyperviscosity.

Finally, HCL has a truly peculiar presentation: patients may be completely asymptomatic but showing at least one peripheral blood cytopenia (mainly thrombocytopenia or neutropenia found upon routine examinations), with a constant lack of circulating monocytes, and a variable degree of splenomegaly. Lymph nodes are generally not enlarged. Upon BM biopsy, always required to establish the diagnosis, hypoplasia is not an infrequent finding, along with an increase in reticulin fibrosis. Both these aspects may concur in causing cytopenias. Some patients, on the other hand, may be severely ill at onset due to a concomitant infection, which is favored by prolonged neutropenia and impaired immune response (57, 60–62). Rare extramedullary or immune-mediated manifestations have also been described (63).

3 The tumor microenvironment: a key player in hematologic malignancies vs. solid tumors

Over time, it has become clear that tumors are not isolated entities, but rather complex diseases involving genetic alterations, metabolic rewiring, persistent inflammation, and immune dysregulation. This understanding has shifted cancer research from a tumor-centric to a TME-centric paradigm, influencing every stage of patient care—from prevention to diagnosis and treatment (64, 65). The TME encompasses a dynamic network of stromal and immune cells, cytokines and chemokines (66), growth factors, extracellular vesicles (EVs) (67), and the extracellular matrix (ECM) (68), all of which interact with tumor cells to shape disease behavior.

In both solid and hematologic malignancies, the TME plays a critical role in promoting tumor progression and therapy resistance (69, 70). However, its structure and function differ markedly between these cancer types. In solid tumors, the TME is spatially confined around the tumor mass and includes cancer-associated fibroblasts, endothelial cells, pericytes, and infiltrating immune cells. Biomechanical signals such as hypoxia, pH gradients, and ECM remodeling influence not only tumor cell behavior but also immune and vascular responses (68, 71, 72). These dynamics contribute to T and Natural killer (NK) cell exhaustion, limiting their infiltration and cytotoxic activity (73). T cell exhaustion is also observed in mature B-cell neoplasms such as HL, DLBCL, and MM (74, 75).

In hematologic malignancies, the TME is more diffuse and systemic, primarily involving the BM, lymph nodes, and spleen. Unlike most organs where solid tumors arise, the BM is physiologically hypoxic, despite its rich vascularization (76, 77). This hypoxia varies across BM niches, with the endosteal niche being more hypoxic and enriched in hypoxia-inducible factor (HIF)-1α-positive cells compared to the vascular niche. Hypoxia plays a role in maintaining hematopoietic stem cells and becomes more pronounced in marrow-infiltrating malignancies like myeloma and lymphoma. In both solid and hematologic tumors, hypoxia triggers adaptive responses via HIFs, promoting angiogenesis, metabolic reprogramming, immune evasion, and resistance to therapy. Solid tumors often develop extensive hypoxic and acidic microenvironments due to rapid growth and poor perfusion, leading to anaerobic glycolysis and extracellular acidification. Hematologic malignancies, while typically lacking solid mass formation, can still generate localized hypoxic niches—especially in BM, but acidification of the tumor milieu is less pronounced (70, 78). Approximately 50–60% of solid tumors develop hypoxic regions (79), whereas hematologic tumors show greater heterogeneity. In leukemia, where malignant cells circulate widely, hypoxia has a limited impact and does not significantly influence endothelial progenitor cell behavior or angiogenesis (80, 81). Nonetheless, increased BM vascular density has been observed in leukemias and MM, suggesting that angiogenesis contributes to disease progression in hematologic cancers as well (82–84).

Metabolic dependencies also differ between tumor types. Leukemic cells are more isolated and highly reliant on specific metabolic pathways, making them particularly vulnerable to metabolic inhibition (85, 86). In contrast, metabolic targeting in solid tumors must be more selective to avoid collateral damage to surrounding non-tumor cells, including immune populations.

Therapeutic strategies increasingly aim to target immunological factors and synergistic changes in the TME to eradicate tumor cells (87). In solid tumors, this includes disrupting angiogenesis, remodeling the ECM, and reactivating immune responses via checkpoint blockade. In hematologic malignancies, interventions focus on disrupting stromal signaling, modulating cytokine networks, and overcoming immune dysfunction.

Exploring the similarities and differences between solid and hematologic tumors in processes such as T-cell depletion, angiogenesis, hypoxia, and metabolic adaptation is crucial for understanding tumor progression dynamics and for identifying targeted therapeutic strategies.

3.1 The role of the tumor microenvironment in mature B-cell neoplasms

As already pointed out, mature malignant B-cells exhibit a specific tropism for lymph nodes, BM, or other secondary lymphoid organs, where they find support of an advantageous niche for their survival and propagation (88–90).

Tumor B-cells themselves secrete chemoattractant chemokines (such as C-C motif chemokine ligand (CCL)3, CCL4) that recruit T cells and monocytes/macrophages and stimulate stromal components (91). Myeloid bystander cells, including tumor associated macrophages, often polarize towards an immunosuppressive phenotype under the influence of factors such as Interleukin (IL)-10, CSF-1, and Transforming Growth Factor (TGF)-β, further promoting tumor cell survival. Other soluble cytokines and growth factors in the TME include IL-4, IL-6, IL-8, Tumor Necrosis Factor (TNF)-α, and cell adhesion molecules such as VCAM-1, which actively contribute to malignant B cell progression (92–94).

In lymph nodes and secondary lymphoid organs, malignant B cells localize in proliferation centers where they engage in intensive cross talk with T cells (especially CD4⁺ helper T cells and Tfh cells), monocyte derived Nurse like cells, follicular dendritic cells, and stromal fibroblasts (28, 95, 96). Interestingly, in CLL a specific role has been described for Nurse like cells, which share features with leukemia-associated macrophages, able to act as an alternative source of CCL21 thereby sequestering malignant B-cells within lymph nodes (97). With a complex bidirectional crosstalk Nurse like cells strongly support CLL cells providing feed and protection from drugs but are also manipulated by leukemic cells in order to create an immunosuppressive milieu that allows immune evasion (95).

In the BM microenvironment, along with perivascular stromal cells, osteoblasts, endothelial cells and resident myeloid cells, a crucial role in tumor progression is played by mesenchymal stromal cells (MSCs) (98) that strongly cooperate with malignant mature B-cells conferring protection from apoptosis and fostering drug resistance with a mechanism involving Notch-1 signaling (99, 100).

B-cells neoplasms establish dynamic interactions with marrow stromal cells, transforming the BM TME into a tumor-supporting niche (101). Depending on the tumor subtype, different patterns of BM infiltration are observed: diffuse infiltration that is associated with an advanced stage and poor prognosis, nodular infiltration (e.g. CLL) that is considered less invasive with better prognosis and interstitial or perivascular infiltration (e.g. CLL, HCL, DLBCL) that represents an intermediate pattern in aggressiveness and clinical impact (86). To date, the mutational status of IgHV gene, distinguishing U CLL from M CLL, has been associated with different patterns of BM infiltration when coupled to ZAP-70 protein expression (102).

In addition to infiltrating the marrow, tumor cells actively modify the niche in an immunosuppressive environment that protects them and drives disease progression. These changes in the microenvironment may precede tumor-inducing mutations in hematopoietic cells, suggesting a non-cell-autonomous model of oncogenesis in which the environment itself contributes to tumor origin (103, 104). These observations reinforce the idea that the BM microenvironment is an active co-protagonist in hematological pathogenesis. For this reason, integrating knowledge of niches into clinical practice may represent a fundamental strategy to improve future treatments, making them more personalized and efficient (90).

Malignant B-cells home to the BM microenvironment through the interaction of their CXCR4 receptor with the stromal-derived factor-1 (CXCL12) and adhere through integrins, particularly with the α4β1 integrin (also known as very late antigen-4, VLA-4) binding to VCAM-1 expressed on mesenchymal and perivascular stromal cells (105). These VCAM-1/VLA-4 adhesion-mediated signals lead to chemoresistance through the activation of NF-κB (106).

In the specific case of MM, malignant plasma cells can affect the bone homeostasis dependent by deposition and resorption of osteoblasts and osteoclast respectively, leading to pathologic bone fractures and bone pain (107). Specifically, it is reported that MM cells are able to block the differentiation of mesenchymal stem cells into osteoblasts by producing both Wnt inhibitors or the epidermal growth factor (EGF) family member amphiregulin (108, 109). Moreover, in the MM bone microenvironment, elevated cytokines (such as TNF-α, interferon (IFN)-gamma, IL-1β, and IL-6) and direct contact with malignant plasma cells trigger osteoblast apoptosis, impairing new bone formation (110).

BM fibrosis and ECM composition play a crucial role in mature B-cell malignancies by supporting tumor survival, drug resistance, and microenvironmental remodeling. In particular, Tancred et al. analyzed the expression and localization of fibronectin, laminin, and collagens I and IV in the core biopsies of normal donors and patients with MM. They reported reduced levels of fibronectin and collagen I in MM patients with high-level plasmacytosis, whereas the expression of collagen IV in the BM of MM patients was higher than in the BM from normal donors (111). These findings have been subsequently confirmed by a proteomic characterization which highlighted the reduction and disorganization of type I collagen (COL1A1/COL1A2) and reported significant upregulation of ECM-associated proteins such as Annexin A2 and Galectin-1, which correlate with a poor prognosis in patients with MM (112). Conversely, in HCL, malignant hairy B-cells actively contribute to the abnormal ECM by synthesizing and assembling an insoluble fibronectin matrix increasing the characteristic BM fibrosis (113). Additionally, HCL is associated with elevated levels of TGF-β1, which stimulates fibroblasts to increase production and deposition of type I and type III procollagens, further altering ECM composition (114). The HCL cells bearing CXCR4 are strongly attracted within a CXCL12 rich microenvironment, highly expressed by stromal cells. HCL cells also secrete TNF-α, which upregulates VCAM-1 on endothelial and stromal cells, thereby enhancing their adhesion and migration. Stromal interactions in HCL can activate downstream signaling via integrin α4β1/VLA-4, triggering NF-κB pathways that sustain proliferation and reduce apoptosis (115). In HCL, the protective role of the microenvironment has been recently emphasized (115).

All these observations reinforce the idea that the tumor microenvironment is an active co-protagonist also in mature B-cell neoplasms. For this reason, integrating knowledge of niches into clinical practice may represent a fundamental strategy to improve future treatments.

3.2 Three-dimensional culture models in mature B-cell neoplasms

Three-dimensional (3D) cell culture models have become essential tools in cancer research, allowing researchers to investigate tumor growth, invasion, and response to therapies framed in a physiologically relevant context able to recapitulate the complex tissue architecture, oxygen gradients, and cell–cell interactions present in vivo (116). The 3D cell culture systems have traditionally been employed to investigate both primary solid tumors (117) and the metastatic process (118, 119). Emerging studies have also demonstrated the potential of 3D models in hematologic malignancies, where, by providing structural and spatial cues, they enable malignant cells to interact with stromal and endothelial counterparts within a more physiologically relevant context. This interaction promotes long-term survival and faithfully reproduces drug resistance mechanisms observed in vivo (120). These models have been successfully applied to both the acute and chronic form of hematological disease (121–123) and specifically in various mature B-cell neoplasms, as summarized in Supplementary Table 1 (124–137). In this context, Barbaglio and collaborators developed a rotational 3D co-culture model using a porous gelatin-based scaffold (Spongostan) seeded with HS5 stromal cells and CLL cells (primary cells) or MEC1 cell line. The Rotating Cell Culture System ensured uniform nutrient diffusion and sustained 3D organization. This dynamic system was designed to functionally replicate the BM microenvironment, emphasizing the cellular cross-talk and retention mechanisms that underlie CLL persistence in vivo. The model effectively captured the cytoskeletal protein hematopoietic lineage cell-specific protein 1 (HS1)- and CXCR4-dependent adhesion, as well as ibrutinib-induced mobilization (124). Furthermore, the same 3D Spongostan-scaffold has been applied for the biophysical modeling of the lymphoid microenvironment, co-culturing stromal and endothelial cells under static and dynamic (by using microfluidic bioreactors) conditions. Unlike the rotational system, this perfusion-based platform enabled fine control of shear stress and fluid flow. In particular the introduction of flow enhanced tissue-like organization with cells aligned along flow trajectories, ECM components deposition (such as fibronectin, laminin, and collagen), and upregulation of mechanotransduction genes (e.g. LMNA, FSCN1, PTK2, ICAM1, VCAM1). Moreover, CLL cells (MEC1 cell line) circulated through the dynamically matured scaffolds displayed enhanced homing and adhesion, behaviors absent in static conditions (125).

Moving beyond conventional two-dimensional cultures toward 3D methods, there are the scaffold-free approaches applied by Ilic et al. in order to investigate the cross-talk between stromal and MM cells (126). Stromal cells spontaneously organized into compact spheroids characterized by reduced metabolic and proliferative activity, hallmarks of a quiescent stromal state. Although this model effectively captured certain aspects of stromal physiology and has also been efficiently applied for CAR-cytotoxicity testing (127), it fell short in reproducing functional MM MSCs interactions, as myeloma cells localized only to the spheroid periphery. The use of a collagen-based co-culture model allows to overcome these limitations, by embedding both MSCs and MM cells within a type I collagen matrix. This configuration supported a more homogeneous cellular organization, maintained stromal chemokine expression (such as CXCL12), and crucially recapitulated drug resistance dynamics, as MM cells displayed reduced sensitivity to bortezomib, consistent with cell adhesion–mediated drug resistance observed in vivo (126). While these models remain simplified representations of the BM niche, they also provide a compelling framework for advancing physiologically relevant 3D platforms in hematological research.

Expanding from myeloma to aggressive B-cell lymphomas, similar 3D approaches have been applied to DLBCL. Foxall et al. developed a physiologically relevant 3D culture system to model DLBCL and its interactions with the TME (128). They integrated fibroblasts (from adipose-derived stem cells), primary human monocyte-derived macrophages, and primary DLBCL tumor cells, all embedded within a type I collagen matrix to form multicellular spheroids. Notably, fibroblasts were functionally polarized into a lymphoid-like stromal phenotype via cytokine stimulation (IL-4, TNF-α, LT-α/β), leading to the expression of key lymphoid stromal markers such as podoplanin, ICAM-1, and VCAM-1. The resulting 3D architecture enabled spatially organized and sustained interactions between tumor, stromal, and immune cells, better approximating the structural complexity of the native lymphoma microenvironment. This system supported the survival of primary DLBCL cells and allowed for the functional investigation of the antibody-dependent cellular phagocytosis (ADCP) immune mechanism in response to rituximab (anti-CD20 mAb). Phagocytosis efficiency was shown to be sensitive to matrix density: higher collagen concentrations impaired ADCP, whereas lower matrix densities facilitated phagocytosis and significantly reduced DLBCL cell viability (128).

A different approach, still within the context of DLBCL, aimed at studying a physiologically relevant microenvironment, has been the use of a bone-derived 3D scaffold model (129). Using decellularized human trabecular bone preserving essential ECM components such as collagen type I, fibronectin, and laminin, the authors reconstructed a structurally and biochemically authentic scaffold capable of supporting stromal and tumor co-cultures. When repopulated with MSCs, the model effectively recreated features of the BM niche, allowing lymphoma–stroma interactions and test the drug-resistance: OCI-LY18 (germinal center B-cell-like) cells exhibited intrinsic resistance to doxorubicin, whereas NU-DUL-1 (activated B-cell-like) cells developed resistance only when co-cultured with MSCs, emphasizing the distinct yet complementary roles of ECM composition and stromal signaling in modulating chemoresistance (129). This study highlights how the native bone-derived ECM can act as both a structural and biochemical determinant of tumor behavior, offering a level of physiological relevance difficult to achieve with synthetic scaffolds. However, the static nature, the lack of vascular or immune components of this method still limits its ability to fully reproduce the complexity of the marrow milieu.

Despite their growing utility in biomedical research, 3D culture systems still face significant technical and translational challenges that hinder their widespread adoption. Reproducibility across laboratories remains a major concern, particularly given the heterogeneity of scaffold-based models, which often vary in physical properties such as stiffness and porosity, affecting experimental outcomes (138). Scaffold-free systems, while useful in certain contexts, are inherently less stable for non-adherent hematologic cells, limiting their applicability. Moreover, dynamic culture platforms, though capable of mimicking physiological conditions more closely, are technically complex and poorly suited for high-throughput workflows. Addressing these limitations will require concerted efforts toward standardization, integration of real-time monitoring technologies, and the development of hybrid platforms that combine biomimetic scaffolds with relevant stromal and immune components under perfused or mechanically active conditions (120).

Considering the relevance of EVs in the dynamics between tumor and TME, it is worth to mention that, to the best of our knowledge, there are currently no studies employing 3D cell culture models to investigate the effects of EVs in mature B-cell neoplasms, nor 3D models specifically developed for the study of HCL. However, it is reported, in a 3D bioreactor system, that the production of EVs from human adipose-derived MSCs resulted increased in concentration and purity compared to traditional 2D cultures, under both normoxic and hypoxic conditions (139). This highlights a critical need for the scientific community to advance toward the adoption of such 3D models in these specific contexts, as they better recapitulate relevant physiological aspects and may provide more accurate insights into disease mechanisms and therapeutic responses.

4 From “Platelet dust” to immune modulators: the evolving understanding of extracellular vesicles

In the late 1960’s, EVs were initially described as “platelet dusts”, cell debris or experimental artifacts (140), while nowadays their existence as lipid bilayer particles released by all cell types under both physiological and pathological conditions and detectable in both tissues (141, 142) and body fluids (143–145) is well established. The growing complexity and heterogeneity of EVs, due to their diverse origins, densities, sizes, and molecular cargos, brought to their classification into distinct populations to refine the comprehension on their biological roles (146). Indeed, according to biogenesis mechanisms, EVs can be classified into the following main categories: I) “exosomes”, secreted upon plasma membrane fusion with multivesicular bodies (MVBs) of endosomal origin (147); II) “microvesicles” and “ectosomes”, plasma membrane-derived microparticles, enriched in cytosolic and plasma membrane-associated proteins (148); III) apoptotic bodies released from cells undergoing programmed cell death or apoptosis and contain both cytosolic components and nuclear fragments (149); IV) the recently emerged population of non-vesicular extracellular nanoparticles, comprising exomeres and supermeres (150, 151).

To date, according to the latest guidelines released by the International Society for Extracellular Vesicles (ISEV) on the minimal information for studies on EVs (MISEV2023), EVs can be categorized based on their size, regardless of the biogenesis mechanism: small EVs (S-EVs), which have a size ≤200 nm, and large EVs (L-EVs) ≥ 200 nm (146).

Interestingly, one of the earliest reports documenting the release of membrane-bound vesicles by tumor cells dates back to 1978, when “rare, pleomorphic membrane-lined particles” were observed in cell lines derived from patients with Hodgkin’s disease (152). This initial observation was soon followed, in 1979, by an independent study that identified plasma-derived vesicles released by murine leukemia cells (153), further supporting the notion that vesicle shedding is a conserved feature of malignant hematopoietic cells. From these pioneering studies, tumor derived EVs have emerged as key messengers in the development of both solid (154) and hematological malignancies (155). The ability to transfer bioactive molecules such as proteins, lipids and nucleic acids (DNA, RNA, miRNA) between tumor cells themselves and microenvironment cells, promotes functions such as angiogenesis (156), tumor cell migration (157, 158) and immune modulation (159).In 1996, antigen-presenting ability of EVs was highlighted for the first time, demonstrating that exosomes derived from B lymphocytes carried both MHC class I and II molecules, allowing them to present tumor antigen peptides to CD8+ and CD4+ T cells, acting as immunostimulatory factors in T cell responses (159). Conversely, EVs have been reported to inhibit the immune system response by hindering immune surveillance and creating an immunosuppressive microenvironment (160, 161).

Altogether, evidence from hematologic tumor microenvironments suggests that EVs are not merely passive byproducts of cellular activity but active mediators of immune modulation, potentially shaping innate and adaptive immunity through the induction of T-cell exhaustion, recruitment of monocytes, and polarization of macrophages toward an M2-like phenotype—as we discuss in detail in the next section.

4.1 Extracellular vesicles: key mediators of immune evasion in mature B-cell malignancies

This overview highlights the central and multifaceted role of EVs as critical mediators of immune modulation and tumor progression across various mature B-cell malignancies, including Lymphoma cHL, DLBCL, MM, CLL.

In cHL, Reed/Sternberg (HRS) cells release CD30+ EVs that stimulate IL-8 release from distant immune cells expressing CD30 ligand (162). IL-8, in turn, can induce immunosuppression by promoting the trafficking of neutrophils and myeloid-derived suppressor cells into the TME (163). Beyond these paracrine effects on innate immune cells, HRS cells engage in bidirectional communication with lymph node MSCs via EVs expressing ADAM10, one of the most prominent members of the Surface-expressed proteases of the disintegrin and metalloproteinase (ADAM) family. In particular, HRS cell-derived EVs induce MSCs to release MHC class I polypeptide–related sequences, whereas MSC-derived EVs stimulate TNF-α and CD30 production by HRS cells, collectively subverting host immune responses (164). In DLBCL, EVs derived from lymphoma B-cells and harboring mutated MYD88 activate proinflammatory signaling in mast cells and macrophages, reshaping the BM microenvironment into a pro-tumorigenic niche (165): however, although MYD88 mutations occur in ~40% of DLBCL, their attribution to DLBCL-derived EVs should be interpreted cautiously, as this mutation is nearly universal in Waldenström’s macroglobulinemia, which evolves into DLBCL in only a small fraction (~10%) of cases (166). Also, DLBCL-EVs promote macrophage M2 polarization via increased PGC-1β expression, facilitating tumor progression (167). EVs containing neuron-specific enolase (NSE) induce M2 polarization by disrupting the NF-κB pathway and enhancing macrophage migration (168). In another report, exosomal NSE have been reported to enhance glycolysis through the GSK3β/β-catenin/c-Myc pathway, driving M2-like macrophage differentiation (169).

EV-associated miRNAs also modulate innate immunity; in particular, acting on both macrophages and NKs functions. Indeed, reduced miR-7e-5p expression in DLBCL cells limits its transfer through EVs, leading to increased Fas Ligand (FASL) expression and activation of apoptotic caspase signaling in M1 macrophages (170); while plasma-derived EVs from DLBCL patients have been reported to suppress NK cell proliferation and cytotoxicity (171). By contrast, DLBCL EVs derived by in vitro cell lines have been reported as able to stimulate dendritic cell-mediated antitumor immunity, inducing T cell clonal expansion and IL-6 and TNF-α secretion, while decreasing the production of IL-4 and IL-10 immunosuppressive cytokines (172), highlighting context-dependent immune effects.

Despite these mechanistic insights, clinical translation remains uneven. Prognostic associations with proteins/miRNAs (173) illustrate the potential of EVs as biomarkers, yet methodological variability and limited integration with patient phenotypes persist. Standardized EV isolation, multi-omic profiling, and careful disease stratification will be essential to translate EV biology into actionable biomarkers and therapeutic targets in B-cell malignancies.

In MM, EVs have emerged as orchestrators of immune suppression, angiogenesis, and BM niche remodeling (174, 175). Regarding the cellular components of the innate immune response, NK cells showed reciprocal tumor-supportive interactions with myeloma cells: under genotoxic stress, MM cells release Heat Shock Protein (HSP)70⁺ EVs that activate NK cells via TLR2/NF-κB, increasing IFN-γ secretion without improving cytotoxicity (176). Conversely, other MM-EVs downregulate activating receptors NKG2D and NKp46, impairing NK-mediated killing (177). Notably, NK-derived EVs containing perforin and granzymes selectively induce apoptosis in drug-resistant MM cells, sparing normal hematopoietic cells (178).

MM-EVs also influence myeloid cells. Under hypoxia, EVs enriched in miR-1305 drive macrophage polarization toward an M2-like phenotype that promotes immunosuppression (179). Among the intercellular communication mechanisms emerged in the cross-talk with adaptive counterparts of the immune system, it has been observed that MM-EVs suppress T-cell activation and effector function through checkpoint molecules such as PD-L1, PD-1, and HLA-G, driving T-cell exhaustion (180). Additionally, EV-associated factors, including IL-8, SLC1A5, and sphingosine kinase-1 (SPHK1), further enhance immunoregulatory signaling (181). MM-EVs also disrupt the balance among CD4⁺, CD8⁺, and regulatory T-cell subsets, reducing cytotoxicity while increasing Treg-mediated suppression (182). Moreover, MM-EVs expressing CD39, CD73, CD38, and CD203a catalyze adenosine production, inhibiting T-cell activity and enhancing M2 polarization (183). MM-EVs interfere with dendritic cell differentiation via TGF-β1 signaling (174) and expand myeloid-derived suppressor cells through STAT3/STAT1 activation (184). Conversely, immune-cell-derived EVs—such as B-cell EVs carrying miR-335—are able to suppress MM by downregulating SOX4 and inhibiting the PI3K/AKT/HIF-1α pathway (185).

Consistent with observations in other hematologic malignancies, CLL-EVs have likewise emerged as pivotal regulators of leukemic biology and immune modulation. Plasma or serum EVs levels are elevated in CLL patients compared with healthy controls (186–190). Interestingly, CLL-EVs promote immune evasion primarily by impairing T-cell function through PD-L1 and TGF-β, suppressing activation and proliferation. They foster the expansion of regulatory T-cells and myeloid-derived suppressor cells while inducing T-cell exhaustion (191, 192). CLL-EVs disrupt T-cell receptor signaling (193) and enhance CD4⁺ T-cell motility and interaction with tumor cells (194). Functionally, these EVs suppress CD8⁺ T-cell cytotoxicity, facilitating leukemia expansion in murine models, where elevated EV-related gene expression correlates with poor survival (195).

In parallel, CLL-EVs downregulate NK cell receptors such as NKG2D, reducing cytotoxic activity (196). They also transfer oncogenic miRNAs, including miR-150 and miR-155, that enhance leukemic B-cell survival (191) and alter normal B-cell function. Exosomal RNA cargo further drives metabolic reprogramming, cell proliferation, and PI3K-mTOR pathway activation (197). Moreover, CLL-EVs exert profound effects on myeloid cells. They reprogram monocytes toward PD-L1⁺ and IL-10–secreting macrophages (191), while M2 macrophage-derived EVs in turn enhance CLL survival (198). Moreover, CLL EVs promote the differentiation of nurse-like cells via RNA-dependent mechanisms (199). Conversely, EVs from NK and cytotoxic T-cells deliver cytotoxic proteins with anti-leukemic effects (200).

In summary, EVs have emerged as central players of immune modulation across mature B-cell malignancies. EV-mediated crosstalk within the TME is highly dynamic and bidirectional, encompassing intricate interactions between malignant cells and various immune subsets through the transfer of bioactive proteins, lipids, and nucleic acids. This leads to immune evasion, tumor growth, and therapy resistance. Despite their shared abilities, the impact of EV-mediated signaling varies among diseases. In cHL and DLBCL, EVs remodel immune and stromal compartments, mainly promoting macrophage polarization and cytokine dysregulation. In MM, they reinforce immune suppression by impairing T and NK cell cytotoxicity while supporting the pro-tumor myeloid niche. Similarly, in CLL, they reprogram the immune response and propagate oncogenic signaling through RNA transfer. Altogether, these findings highlight EVs as pivotal mediators in the interplay between cancer and the immune system, acting both as facilitators of immune escape and as emerging targets for therapeutic intervention—thus opening new avenues in precision oncology.

Although no published data currently exist on EVs in HCL, the disease is characterized by BM fibrosis and profound cytopenias, which are clinically associated with a markedly increased susceptibility to infections. This underscores that immune cells are not only locally affected—through stromal remodeling and the migration and expansion of HCL cells within the marrow—but are also systemically compromised. The immunological dysregulation in HCL represents a central axis of disease progression, with systemic immunosuppression exposing patients to recurrent and potentially life-threatening infections. On this basis, a multicenter clinical trial (NCT06774677) is underway to investigate how HCL-derived EVs modulate key components of the TME, including immune and stromal elements, with the aim of elucidating their role in both local niche conditioning and systemic immune impairment. Figure 2 resumes what we have pointed out in the present section.

Figure 2

4.2 Extracellular vesicles and stromal–ECM remodeling: implications for bone marrow fibrosis in HCL

To mediate cell-to-cell communication, EVs must traverse the ECM from their cell of origin to recipient cells. Recent studies on ECM stress relaxation have shown that the mechanical properties of both the ECM and EVs enable their diffusion through the extracellular space, despite EVs having a larger diameter than the ECM mesh width (201).

In solid malignancies, EVs have been extensively reported to carry matrix metalloproteinases (MMPs), which play a central role in ECM remodeling. These enzymes not only degrade ECM components (141, 202) but also modulate signaling molecules within the extracellular space (203). In MM, exosomes released by hypoxic cells have been shown to contain elevated levels of heparanase, a proteolytic enzyme that cleaves heparan sulfate—an ECM-integrated glycosaminoglycan or cell surface component (204, 205). This activity promotes macrophage migration, invasion, and endothelial tube formation (206). Additionally, MM-derived EVs are enriched in surface fibronectin, which facilitates binding to heparan sulfate on target cells and mediates exosome–cell interactions (207). In cHL, EVs have been shown to express ADAM10, an enzyme responsible for ectodomain shedding. These ADAM10-active EVs can remotely influence recipient cells by serving as platforms for shedding processes, thereby extending the functional reach of cHL cells and shaping the immune response and tumor microenvironment beyond the primary site (164). E. Dumontet and colleagues have reviewed how the TME adapts in mature B-cell neoplasms, particularly within BM and lymph node niches, emphasizing the role of EVs in these process (89). In CLL, microvesicles detected in peripheral blood deliver the receptor tyrosine kinase Axl to BM stromal cells, activating the AKT/mTOR/p70S6K/HIF-1α axis and increasing VEGF synthesis (189). However, no studies have yet investigated the role of EVs in establishing a BM stromal niche in DLBCL. Although the involvement of EVs in HCL remains unexplored, a clinical trial (NCT06774677) is currently investigating their potential role in ECM–stromal remodeling, particularly in BM fibrosis. Central pathways driving fibrosis in HCL have been recently summarized (208). HCL cells bind hyaluronan—another ECM glycosaminoglycan—via CD44, leading to the release of FGF-2 into the intercellular matrix (209). This autocrine loop stimulates FGFR1 signaling and promotes fibronectin production (210, 211). Additionally, BM fibrosis is sustained by TGF-β–activated fibroblasts that produce collagen. Figure 2 resumes what we have pointed out in the present section.

Recent findings in cardiac fibrosis offer further insight: activated BM cells release EVs enriched in miR-21a-5p, which upregulates Integrin αV (ITGAV) and enhances the synthesis of ECM proteins, particularly collagen type I alpha (Col1α), contributing to fibrotic remodeling (212).

These converging lines of evidence support the hypothesis that EVs may act as key modulators of ECM remodeling and fibrosis in HCL, warranting further investigation into their mechanistic roles and therapeutic potential.

5 Extracellular vesicles in hematology: infrastructure, methodology, and the unmet need in HCL

In hematological malignancies, national initiatives enable access to biological samples and clinical data. Disease-specific infrastructures for mature B-cell neoplasms include the UK CLL Biobank (UK), FILOThèque (France, CLL/AML), Blood Cancer Network Ireland (BCNI), and HEMLYM Biobank (Netherlands). The HARMONY Alliance integrates clinical and molecular data for AML, ALL, CML, and MM, creating a large-scale big data platform. Similarly, ENROL (EuroBloodNet) promotes registry harmonization for rare hematologic diseases. However, no dedicated biobank exists for HCL, revealing a major research gap. Blood Cancer United (LLS) supports research and patient services across blood cancers, including HCL. The HCL Foundation (USA) uniquely focuses on HCL, funding research and patient education. Biobanks enable standardized sample use, advancing rare disease research and precision medicine. Transparent procedures remain essential for reproducibility and reliability in translational research (213–215).

Within this framework, collection, storage and characterization of EVs – together with the definition of universal biomarker of EV characterization - remain critical methodological gaps that need to be addressed (213, 216). Both pre-analytical and analytical parameters critically affect the quantitative and qualitative evaluation of EVs. Pre-analytical variables such as blood collection procedures, sample processing, and storage conditions significantly influence EV yield, size distribution, and molecular composition (216, 217). Analytical variability—including isolation strategy, quantification method and marker selection —further contributes to inter-laboratory discrepancies (146). The harmonization of pre-analytical procedures, as promoted by national initiatives such as the GEIVEX strategy (Grupo Español de Investigación en Vesiculas Extracelulares) (216), represents an example of efforts to identify pre-analytical barriers through a web-survey, and promote a standardized workflows to reduce inter-laboratory variability. In addition, systematic collection of pre-analytical metadata is critical to identify hidden biases that may influence the characterization and analysis of EVs from biofluids. In this direction, the MIBlood-EV initiative (217). Minimal Information for Blood EV research, recently launched by the ISEV Blood EV Task Force, provides a reporting framework designed to: improve the quality of biobanking, promote the exchange between biobanks and laboratories of samples, facilitate inter-laboratory comparability of EV studies (218). Similarly, even analytical variability remains a major issue, as significantly affect the measurable fraction of circulating EVs (219). To address these challenges, the recently updated MISEV 2023 guidelines provide comprehensive recommendations for EVs isolation, characterization and functional studies reinforcing methodological rigor and reproducibility throughout all experimental stages of EVs research (146). In Italy, national initiative INNOVA – Italian network of excellence for advanced diagnostics (PNC- E3-2022–23683266 DIAGNOSTICA AVANZATA (HLS-DA) (https://www.innovaplatform.it/) - a Hub & Spoke network funded by the Italian Ministry of Health, aims to develop and disseminate standardized and advanced diagnostic methodologies across the country, integrating wet laboratory and bioimaging technologies that supports multistakeholder collaborations at both national and international levels. Taken together, these observations highlight that, although EVs are intrinsically stable structures, their quantitative and qualitative assessment is highly dependent on both pre-analytical and analytical factors. Therefore, establishing standardized and reproducible protocols for EVs is essential to ensure the reliability of their use as biomarkers or therapeutic agents (220). It follows that clinical trials can more reliably investigate the diagnostic, prognostic and therapeutic potential of EVs. The integration of clinical and biological data within clinical trials is essential to support target discovery, biomarker identification and patient stratification, fostering translational and collaborative projects (213). Although most ongoing clinical trials involving EVs are focused on solid tumors, their diagnostic and therapeutic potential in B-cell malignancies is increasingly acknowledged (221). A recent systematic review of EVs in clinical trials reported that, among them, nearly half (47.3%) of registered studies aimed at diagnostic, 33.3% of trials investigated companion diagnostics, the remaining 19.3% explored therapeutics applications (222). Methodological heterogeneity remains a key limitation (222). In this evolving landscape, the ongoing Italian multicenter, experimental, cross-sectional, non-profit clinical trial “Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management” (NCT06774677), represents a significant step forward. It aims to elucidate how EVs derived from HCL cells contribute to immune dysfunction and BM fibrosis, potentially identifying an EV-based molecular signature associated with outcomes. As a result, integrating these rigorous practices will create a favorable landscape for translating preclinical discoveries into clinical application, providing new perspectives for hematological rare diseases in personalized medicine.

6 Conclusion

In summary, mature B-cell malignancies recapitulate many fundamental features of solid tumor microenvironments—including immune suppression, cytokine-mediated stromal remodeling, metabolic reprogramming, and hypoxia-driven adaptation—while maintaining distinctive hallmarks imposed by the organized architecture of lymphoid tissues and BM niches. Through the exploitation of homing and adhesion pathways, particularly the CXCR4–CXCL12 and VLA-4/VCAM-1 axes, malignant B cells establish reciprocal interactions with stromal and immune components that promote survival, drug resistance, and immune evasion (105). Unlike solid tumors, where the microenvironment is spatially confined, B-cell neoplasms orchestrate dynamic and systemic remodeling of multiple tissue niches, resulting in a diffuse yet functionally integrated tumor ecosystem (101). Comparative analysis of solid and hematologic TMEs may therefore uncover shared vulnerabilities and guide the development of therapeutic strategies aimed at disrupting protective niches and restoring effective anti-tumor immunity (64). Beyond the broad comparison between solid and hematologic TMEs, it is important to recognize that even within the BM, distinct homing niches coexist and evolve throughout disease progression. In MM, malignant plasma cells primarily colonize perivascular and endosteal regions, where interactions with osteoblasts, endothelial cells, and mesenchymal stromal cells foster immune evasion and bone destruction (107). In contrast, HCL cells preferentially reside in reticular and fibrotic areas enriched in CXCL12 and VCAM-1, which sustain their adhesion and survival through VLA-4– and NF-κB–dependent signaling. DLBCL exhibits a more heterogeneous marrow tropism, with interstitial or perivascular infiltration patterns that correlate with disease aggressiveness and clinical stage. These examples highlight that the BM cannot be regarded as a uniform sanctuary, but rather as a mosaic of specialized microanatomical niches whose composition, vascularization, and cellular cross talk are profoundly shaped by tumor subtype and progression (86). Understanding this intra-marrow heterogeneity will be essential to design therapeutic strategies capable of targeting the spatial and temporal diversity of tumor-supportive niches in B-cell malignancies (90). Finally, growing evidence highlights the multifaceted role of EVs in orchestrating ECM remodeling across hematologic malignancies (223) suggesting their potential involvement in the fibrotic processes characteristic of HCL. By integrating mechanical adaptability with bioactive cargo delivery, EVs may contribute to both local stromal reprogramming and systemic disease progression. Elucidating their function in HCL could not only deepen our understanding of marrow fibrosis but also unveil novel therapeutic targets for intervention.

References

• 1

  BispoJABPinheiroPSKobetzEK. Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harb Perspect Med. (2020) 10:a034819. doi: 10.1101/cshperspect.a034819

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 2

  YangHXunYKeCTateishiKYouH. Extranodal lymphoma: pathogenesis, diagnosis and treatment. Mol BioMed. (2023) 4:29. doi: 10.1186/s43556-023-00141-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 3

  de LevalLGaulardPDoganA. A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas. Blood. (2024) 144:1855–72. doi: 10.1182/blood.2023021786

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 4

  WeberALRahemtullahAFerryJA. Hodgkin and non-Hodgkin lymphoma of the head and neck: clinical, pathologic, and imaging evaluation. Neuroimaging Clin N Am. (2003) 13:371–92. doi: 10.1016/s1052-5149(03)00039-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 5

  MontagueAMPathakS. Chronic lymphocytic leukemia with variant genetics. In: StatPearls. StatPearls Publishing, Treasure Island (FL (2025). Available online at: http://www.ncbi.nlm.nih.gov/books/NBK585059/.

  • Pubmed Abstract
  • Google Scholar

• 6

  BouroncleBAWisemanBKDoanCA. Leukemic reticuloendotheliosis. Blood. (1958) 13:609–30. doi: 10.1182/blood.V13.7.609.609

  • CrossRef
  • Google Scholar

• 7

  RoodmanGD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis. (2004) 32:290–2. doi: 10.1016/j.bcmd.2004.01.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 8

  HarrisNLJaffeESSteinHBanksPMChanJKClearyMLet al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. (1994) 84:1361–92. doi: 10.1182/blood.V84.5.1361.1361

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 9

  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The non-hodgkin’s lymphoma classification project. Blood. (1997) 89:3909–18. doi: 10.1182/blood.V89.11.3909

  • CrossRef
  • Google Scholar

• 10

  MathéGRappaportHO’ConnorGT. Histological and cytological typing of neoplastic diseases of hematopoietic and lymphoid tissues. Geneva: World Health Organization (1976). p. 45.

  • Google Scholar

• 11

  JaffeESHarrisNLSteinHVardimanJW. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. 3rd Edition. Lyon: IARC Press (2001). WHO Classification of Tumors.

  • Google Scholar

• 12

  CampoESwerdlowSHHarrisNLPileriSSteinHJaffeES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. (2011) 117:5019–32. doi: 10.1182/blood-2011-01-293050

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13

  SwerdlowSHCampoEPileriSAHarrisNLSteinHSiebertRet al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. (2016) 127:2375–90. doi: 10.1182/blood-2016-01-643569

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 14

  CampoEJaffeESCookJRQuintanilla-MartinezLSwerdlowSHAndersonKCet al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. (2022) 140:1229–53. doi: 10.1182/blood.2022015851

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 15

  AlaggioRAmadorCAnagnostopoulosIAttygalleADAraujoIBDOBertiEet al. The 5th edition of the world health organization classification of hematolymphoid tumors: lymphoid neoplasms. Leukemia. (2022) 36:1720–48. doi: 10.1038/s41375-022-01620-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 16

  PandaDDasNThakralDGuptaR. Genomic landscape of mature B-cell non-Hodgkin lymphomas - an appraisal from lymphomagenesis to drug resistance. J Egypt Natl Canc Inst. (2022) 34:52. doi: 10.1186/s43046-022-00154-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 17

  ShingletonJWangJBalohCDaveTDavisNHappLet al. Non-hodgkin lymphomas: Malignancies arising from mature B cells. Cold Spring Harb Perspect Med. (2021) 11:a034843. doi: 10.1101/cshperspect.a034843

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 18

  TerasLRDeSantisCECerhanJRMortonLMJemalAFlowersCR. 2016 US lymphoid Malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. (2016) 66:443–59. doi: 10.3322/caac.21357

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 19

  WiberMMaitreEPoncetJ-MDuchenetVDamajGCornetEet al. A population-based study of hairy cell leukemia over a period of 20 years. Cancer Treat Res Commun. (2020) 25:100236. doi: 10.1016/j.ctarc.2020.100236

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 20

  MortonLMWangSSDevesaSSHartgePWeisenburgerDDLinetMS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. (2006) 107:265–76. doi: 10.1182/blood-2005-06-2508

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 21

  JanusARobakT. Hairy cell leukemia. In: LiW, editor. Leukemia. Exon Publications, Brisbane (AU (2022). Available online at: http://www.ncbi.nlm.nih.gov/books/NBK586203/.

  • Google Scholar

• 22

  AlthwaiqebSAFakoyaAOBordoniB. Histology, B-cell lymphocyte. In: StatPearls. StatPearls Publishing, Treasure Island (FL (2025). Available online at: http://www.ncbi.nlm.nih.gov/books/NBK560905/.

  • Pubmed Abstract
  • Google Scholar

• 23

  NatkunamY. The biology of the germinal center. Hematol Am Soc Hematol Educ Program. (2007) 2007(1):210–5. doi: 10.1182/asheducation-2007.1.210

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 24

  VictoraGDNussenzweigMC. Germinal centers. Annu Rev Immunol. (2022) 40:413–42. doi: 10.1146/annurev-immunol-120419-022408

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 25

  AlaggioRAmadorCAnagnostopoulosIAttygalleADde Oliveira AraujoIBBertiEet al. Correction: “The 5th edition of the world health organization classification of hematolymphoid tumors: lymphoid neoplasms” Leukemia. 2022 jul;36(7):1720-1748. Leukemia. (2023) 37:1944–51. doi: 10.1038/s41375-023-01962-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 26

  LópezCFischerARosenwaldASiebertROttGKurzKS. Genetic alterations in mature B- and T-cell lymphomas - a practical guide to WHO-HAEM5. Med Genet. (2024) 36:59–73. doi: 10.1515/medgen-2024-2005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 27

  RotbainECFrederiksenHHjalgrimHRostgaardKEgholmGJZahediBet al. IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study. Hematologica. (2020) 105:1621–9. doi: 10.3324/haematol.2019.220194

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 28

  BurgerJAGhiaPRosenwaldACaligaris-CappioF. The microenvironment in mature B-cell Malignancies: a target for new treatment strategies. Blood. (2009) 114:3367–75. doi: 10.1182/blood-2009-06-225326

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 29

  International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. (2016) 17:779–90. doi: 10.1016/S1470-2045(16)30029-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30

  EichhorstBRobakTMontserratEGhiaPNiemannCUKaterAPet al. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2021) 32:23–33. doi: 10.1016/j.annonc.2020.09.019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31

  ShimkusGNonakaT. Molecular classification and therapeutics in diffuse large B-cell lymphoma. Front Mol Biosci. (2023) 10:1124360. doi: 10.3389/fmolb.2023.1124360

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32

  RuanJ. Molecular profiling and management of mantle cell lymphoma. Hematol Am Soc Hematol Educ Program. (2019) 2019:30–40. doi: 10.1182/hematology.2019000011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 33

  FaliniBMartelliMPTiacciE. BRAF V600E mutation in hairy cell leukemia: from bench to bedside. Blood. (2016) 128:1918–27. doi: 10.1182/blood-2016-07-418434

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 34

  LakiotakiELevidouGAngelopoulouMKAdamopoulosCPangalisGRassidakisGet al. Potential role of AKT/mTOR signaling proteins in hairy cell leukemia: association with BRAF/ERK activation and clinical outcome. Sci Rep. (2016) 6:21252. doi: 10.1038/srep21252

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 35

  FritzCWongDPRockPBurackRRadhakrishnanAParameswaranR. Cell therapy for a rare disease- hairy cell leukemia variant. Oncoimmunology. (2024) 13:2432062. doi: 10.1080/2162402X.2024.2432062

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 36

  WangSS. Epidemiology and etiology of diffuse large B-cell lymphoma. Semin Hematol. (2023) 60:255–66. doi: 10.1053/j.seminhematol.2023.11.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 37

  HuberDVoith Von VoithenbergLKaigalaGV. Fluorescence in situ hybridization (FISH): History, limitations and what to expect from micro-scale FISH? Micro Nano Eng. (2018) 1:15–24. doi: 10.1016/j.mne.2018.10.006

  • CrossRef
  • Google Scholar

• 38

  BassoK. Biology of germinal center B cells relating to lymphomagenesis. Hemasphere. (2021) 5:e582. doi: 10.1097/HS9.0000000000000582

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 39

  YadavDPatil-TakbhateBKhandagaleABhawalkarJTripathySKhopkar-KaleP. Next-Generation sequencing transforming clinical practice and precision medicine. Clin Chim Acta. (2023) 551:117568. doi: 10.1016/j.cca.2023.117568

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 40

  QuestGRJohnstonJB. Clinical features and diagnosis of hairy cell leukemia. Best Pract Res Clin Hematol. (2015) 28:180–92. doi: 10.1016/j.beha.2015.10.017

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 41

  HigginsRABlankenshipJEKinneyMC. Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. Arch Pathol Lab Med. (2008) 132:441–61. doi: 10.5858/2008-132-441-AOIITD

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 42

  National Academies of Sciences. Advances in the diagnosis and Evaluation of Disabling Physical Health Conditions. Available online at: https://www.ncbi.nlm.nih.gov/books/NBK593683.

  • Google Scholar

• 43

  ChoJ. Basic immunohistochemistry for lymphoma diagnosis. Blood Res. (2022) 57:55–61. doi: 10.5045/br.2022.2022037

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 44

  SeegmillerACHsiEDCraigFE. The current role of clinical flow cytometry in the evaluation of mature B-cell neoplasms. Cytomet B Clin Cytom. (2019) 96:20–9. doi: 10.1002/cyto.b.21756

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 45

  BoydSDNatkunamYAllenJRWarnkeRA. Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results. Appl Immunohistochem Mol Morphol. (2013) 21:116–31. doi: 10.1097/PAI.0b013e31825d550a

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 46

  Mesquita JúniorDAraújoJAPCatelanTTTde SouzaAWSCruvinel W deMAndradeLECet al. Immune system - part II: basis of the immunological response mediated by T and B lymphocytes. Rev Bras Reumatol. (2010) 50:552–80. doi: 10.1590/S0482-50042010000500008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 47

  RawstronACOrfaoABeksacMBezdickovaLBrooimansRABumbeaHet al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Hematologica. (2008) 93:431–8. doi: 10.3324/haematol.11080

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 48

  MatutesE. Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematol Oncol Clin North Am. (2006) 20:1051–63. doi: 10.1016/j.hoc.2006.06.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 49

  KroftSHHarringtonAM. Flow cytometry of B-cell neoplasms. Clin Lab Med. (2017) 37:697–723. doi: 10.1016/j.cll.2017.07.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 50

  Beatriz Álvarez FloresMSopeña CorvinosMMedrano ÉlezMSoto Del PechoBConejo SánchezLGarcía de la FeJet al. A new approach to the study of Hodgkin lymphoma by flow cytometry. Pathology. (2023) 55:86–93. doi: 10.1016/j.pathol.2022.07.005

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 51

  HansCPWeisenburgerDDGreinerTCGascoyneRDDelabieJOttGet al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. (2004) 103:275–82. doi: 10.1182/blood-2003-05-1545

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 52

  RenaudLDonzelMDecroocqJDecazesPGaltierJBurroniBet al. Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines. Eur J Cancer. (2025) 220:115369. doi: 10.1016/j.ejca.2025.115369

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 53

  RawstronACKreuzerK-ASoosapillaASpacekMStehlikovaOGambellPet al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonization project. Cytomet B Clin Cytom. (2018) 94:121–8. doi: 10.1002/cyto.b.21595

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 54

  HallekMChesonBDCatovskyDCaligaris-CappioFDighieroGDöhnerHet al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. (2018) 131:2745–60. doi: 10.1182/blood-2017-09-806398

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 55

  IsaacKMPortellCAWilliamsME. Leukemic variant of mantle cell lymphoma: clinical presentation and management. Curr Oncol Rep. (2021) 23:102. doi: 10.1007/s11912-021-01094-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 56

  WangH-YZuY. Diagnostic algorithm of common mature B-cell lymphomas by immunohistochemistry. Arch Pathol Lab Med. (2017) 141:1236–46. doi: 10.5858/arpa.2016-0521-RA

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 57

  FaliniBTiacciELisoABassoKSabattiniEPaciniRet al. Simple diagnostic assay for hairy cell leukemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet. (2004) 363:1869–70. doi: 10.1016/S0140-6736(04)16356-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 58

  GreverMRBlachlyJSAndritsosLA. Hairy cell leukemia: Update on molecular profiling and therapeutic advances. Blood Rev. (2014) 28:197–203. doi: 10.1016/j.blre.2014.06.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 59

  HarjunpääHLlort AsensMGuentherCFagerholmSC. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. Front Immunol. (2019) 10:1078. doi: 10.3389/fimmu.2019.01078

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 60

  GreverMRAbdel-WahabOAndritsosLABanerjiVBarrientosJBlachlyJSet al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. (2017) 129:553–60. doi: 10.1182/blood-2016-01-689422

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 61

  RobakTMatutesECatovskyDZinzaniPLBuskeCESMO Guidelines Committee. Hairy cell leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2015) 26 Suppl 5:v100–107. doi: 10.1093/annonc/mdv200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 62

  TiacciETrifonovVSchiavoniGHolmesAKernWMartelliMPet al. BRAF mutations in hairy-cell leukemia. N Engl J Med. (2011) 364:2305–15. doi: 10.1056/NEJMoa1014209

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 63

  RobakTBraunMJanusAGuminskaARobakE. Rare clinical symptoms in hairy cell leukemia: an overview. Cancers (Basel). (2024) 16:3054. doi: 10.3390/cancers16173054

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 64

  MoJZhangHSwarbrickA. TiME for a change: The tumor microenvironment as the missing piece in cancer therapeutics. PloS Biol. (2025) 23:e3003276. doi: 10.1371/journal.pbio.3003276

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 65

  HanahanDWeinbergRA. Hallmarks of cancer: the next generation. Cell. (2011) 144:646–74. doi: 10.1016/j.cell.2011.02.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 66

  JiaQWangAYuanYZhuBLongH. Heterogeneity of the tumor immune microenvironment and its clinical relevance. Exp Hematol Oncol. (2022) 11:24. doi: 10.1186/s40164-022-00277-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 67

  SharmaASinghAPSinghS. Shaping up the tumor microenvironment: extracellular vesicles as important intermediaries in building a tumor-supportive cellular network. Cancers (Basel). (2023) 15:501. doi: 10.3390/cancers15020501

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 68

  PengHChaoZWangZHaoXXiZMaSet al. Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications. Exp Hematol Oncol. (2025) 14:4. doi: 10.1186/s40164-024-00591-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 69

  GiraldoNASanchez-SalasRPeskeJDVanoYBechtEPetitprezFet al. The clinical role of the TME in solid cancer. Br J Cancer. (2019) 120:45–53. doi: 10.1038/s41416-018-0327-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 70

  FiorcariSStratiPDondiE. Editorial: Tumor microenvironment and hematological Malignancies: new evidences and new questions. Front Immunol. (2024) 15:1407981. doi: 10.3389/fimmu.2024.1407981

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 71

  ManciniSJCBalabanianKCorreIGavardJLazennecGLe Bousse-KerdilèsM-Cet al. Deciphering tumor niches: lessons from solid and hematological Malignancies. Front Immunol. (2021) 12:766275. doi: 10.3389/fimmu.2021.766275

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 72

  WendongYJialiJQiaomeiFYayunWXianzeXZhengSet al. Biomechanical forces and force-triggered drug delivery in tumor neovascularization. BioMed Pharmacother. (2024) 171:116117. doi: 10.1016/j.biopha.2023.116117

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 73

  NairRSomasundaramVKuriakoseAKrishnSRRabenDSalazarRet al. Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies. Front Immunol. (2025) 16:1548234. doi: 10.3389/fimmu.2025.1548234

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 74

  García-DomínguezDJHontecillas-PrietoLPalazón-CarriónNJiménez-CorteganaCSánchez-MargaletVde la Cruz-MerinoL. Tumor immune microenvironment in lymphoma: focus on epigenetics. Cancers (Basel). (2022) 14:1469. doi: 10.3390/cancers14061469

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 75

  DesantisVSavinoFDScaringellaAPotenzaMANacciCFrassanitoMAet al. The leading role of the immune microenvironment in multiple myeloma: A new target with a great prognostic and clinical value. J Clin Med. (2022) 11:2513. doi: 10.3390/jcm11092513

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 76

  ChristodoulouCSpencerJAYehS-CATurcotteRKokkaliarisKDPaneroRet al. Live-animal imaging of native hematopoietic stem and progenitor cells. Nature. (2020) 578:278–83. doi: 10.1038/s41586-020-1971-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 77

  SpencerJAFerraroFRoussakisEKleinAWuJRunnelsJMet al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature. (2014) 508:269–73. doi: 10.1038/nature13034

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 78

  BigosKJQuilesCGLunjSSmithDJKrauseMTroostEGet al. Tumor response to hypoxia: understanding the hypoxic tumor microenvironment to improve treatment outcome in solid tumors. Front Oncol. (2024) 14:1331355. doi: 10.3389/fonc.2024.1331355

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 79

  LiaoCLiuXZhangCZhangQ. Tumor hypoxia: From basic knowledge to therapeutic implications. Semin Cancer Biol. (2023) 88:172–86. doi: 10.1016/j.semcancer.2022.12.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 80

  IrigoyenMGarcía-RuizJCBerraE. The hypoxia signaling pathway in hematological Malignancies. Oncotarget. (2017) 8:36832–44. doi: 10.18632/oncotarget.15981

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 81

  HarrisBSaleemSCookNSearleE. Targeting hypoxia in solid and hematological Malignancies. J Exp Clin Cancer Res. (2022) 41:318. doi: 10.1186/s13046-022-02522-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 82

  MittalKEbosJRiniB. Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond. Semin Oncol. (2014) 41:235–51. doi: 10.1053/j.seminoncol.2014.02.007

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 83

  SchmidtTCarmelietP. Angiogenesis: a target in solid tumors, also in leukemia? Hematol Am Soc Hematol Educ Program. (2011) 2011:1–8. doi: 10.1182/asheducation-2011.1.1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 84

  RajkumarSVMesaRATefferiA. A review of angiogenesis and anti-angiogenic therapy in hematologic Malignancies. J Hematother Stem Cell Res. (2002) 11:33–47. doi: 10.1089/152581602753448522

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 85

  YuZZhouXWangX. Metabolic reprogramming in hematologic Malignancies: advances and clinical perspectives. Cancer Res. (2022) 82:2955–63. doi: 10.1158/0008-5472.CAN-22-0917

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 86

  HeXKashyapMKZhaoZJYuJShiH. Editorial: Linking cellular metabolism to hematological Malignancies. Front Oncol. (2022) 12:1077358. doi: 10.3389/fonc.2022.1077358

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 87

  ForteDKrauseDSAndreeffMBonnetDMéndez-FerrerS. Updates on the hematologic tumor microenvironment and its therapeutic targeting. Hematologica. (2019) 104:1928–34. doi: 10.3324/haematol.2018.195396

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 88

  ShainKHDaltonWSTaoJ. The tumor microenvironment shapes hallmarks of mature B-cell Malignancies. Oncogene. (2015) 34:4673–82. doi: 10.1038/onc.2014.403

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 89

  DumontetEManciniSJCTarteK. Bone marrow lymphoid niche adaptation to mature B cell neoplasms. Front Immunol. (2021) 12:784691. doi: 10.3389/fimmu.2021.784691

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 90

  RaaijmakersMHGP. Niche contributions to oncogenesis: emerging concepts and implications for the hematopoietic system. Hematologica. (2011) 96:1041–8. doi: 10.3324/haematol.2010.028035

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 91

  HartmannEMRudeliusMBurgerJARosenwaldA. CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates. Leuk Lymphoma. (2016) 57:563–71. doi: 10.3109/10428194.2015.1068308

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 92

  MangoliniMRingshausenI. Bone marrow stromal cells drive key hallmarks of B cell Malignancies. Int J Mol Sci. (2020) 21:1466. doi: 10.3390/ijms21041466

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 93

  NgWLAnsellSMMondelloP. Insights into the tumor microenvironment of B cell lymphoma. J Exp Clin Cancer Res. (2022) 41:362. doi: 10.1186/s13046-022-02579-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 94

  KlineMDonovanKWellikLLustCJinWMoon-TassonLet al. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. Leuk Res. (2007) 31:591–8. doi: 10.1016/j.leukres.2006.06.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 95

  FiorcariSMaffeiRAteneCGPotenzaLLuppiMMarascaR. Nurse-like cells and chronic lymphocytic leukemia B cells: A mutualistic crosstalk inside tissue microenvironments. Cells. (2021) 10:217. doi: 10.3390/cells10020217

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 96

  PandeySMourcinFMarchandTNayarSGuirriecMPangaultCet al. IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma. Blood. (2017) 129:2507–18. doi: 10.1182/blood-2016-08-737239

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 97

  ZaaboubRVimeuxLContremoulinsVCymbalistaFLévyVDonnadieuEet al. Nurselike cells sequester B cells in disorganized lymph nodes in chronic lymphocytic leukemia via alternative production of CCL21. Blood Adv. (2022) 6:4691–704. doi: 10.1182/bloodadvances.2021006169

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 98

  MaisoPMogollónPOcioEMGarayoaM. Bone marrow mesenchymal stromal cells in multiple myeloma: their role as active contributors to myeloma progression. Cancers (Basel). (2021) 13:2542. doi: 10.3390/cancers13112542

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 99

  NefedovaYChengPAlsinaMDaltonWSGabrilovichDI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other Malignant lymphoid cell lines. Blood. (2004) 103:3503–10. doi: 10.1182/blood-2003-07-2340

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 100

  Nwabo KamdjeAHBassiGPacelliLMalpeliGAmatiENicheleIet al. Role of stromal cell-mediated Notch signaling in CLL resistance to chemotherapy. Blood Cancer J. (2012) 2:e73. doi: 10.1038/bcj.2012.17

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 101

  HughesAMKuekVKotechaRSCheungLC. The bone marrow microenvironment in B-cell development and Malignancy. Cancers (Basel). (2022) 14:2089. doi: 10.3390/cancers14092089

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 102

  WiestnerARosenwaldABarryTSWrightGDavisREHenricksonSEet al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. (2003) 101:4944–51. doi: 10.1182/blood-2002-10-3306

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 103

  Méndez-FerrerSBonnetDSteensmaDPHasserjianRPGhobrialIMGribbenJGet al. Bone marrow niches in hematological Malignancies. Nat Rev Cancer. (2020) 20:285–98. doi: 10.1038/s41568-020-0245-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 104

  KrauseDSScaddenDT. A hostel for the hostile: the bone marrow niche in hematologic neoplasms. Hematologica. (2015) 100:1376–87. doi: 10.3324/haematol.2014.113852

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 105

  HärzschelAZucchettoAGatteiVHartmannTN. VLA-4 expression and activation in B cell Malignancies: functional and clinical aspects. Int J Mol Sci. (2020) 21:2206. doi: 10.3390/ijms21062206

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 106

  JacamoRChenYWangZMaWZhangMSpaethELet al. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance. Blood. (2014) 123:2691–702. doi: 10.1182/blood-2013-06-511527

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 107

  CorreJMahtoukKAttalMGadelorgeMHuynhAFleury-CappellessoSet al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia. (2007) 21:1079–88. doi: 10.1038/sj.leu.2404621

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 108

  OshimaTAbeMAsanoJHaraTKitazoeKSekimotoEet al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. (2005) 106:3160–5. doi: 10.1182/blood-2004-12-4940

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 109

  MahtoukKHoseDRèmeTDe VosJJourdanMMoreauxJet al. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene. (2005) 24:3512–24. doi: 10.1038/sj.onc.1208536

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 110

  SilvestrisFCafforioPCalvaniNDammaccoF. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and Malignant plasma cells. Br J Haematol. (2004) 126:475–86. doi: 10.1111/j.1365-2141.2004.05084.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 111

  TancredTMBelchARReimanTPilarskiLMKirshnerJ. Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance. J Histochem Cytochem. (2009) 57:239–47. doi: 10.1369/jhc.2008.952200

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 112

  GlaveySVNabaAManierSClauserKTahriSParkJet al. Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. Leukemia. (2017) 31:2426–34. doi: 10.1038/leu.2017.102

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 113

  BurthemJCawleyJC. The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells. Blood. (1994) 83:497–504. doi: 10.1182/blood.V83.2.497.497

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 114

  ShehataMSchwarzmeierJDHilgarthMHubmannRDuechlerMGisslingerH. TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia. J Clin Invest. (2004) 113:676–85. doi: 10.1172/JCI19540

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 115

  GargiuloEGiordanoMNiemannCUMoussayEPaggettiJMorandePE. The protective role of the microenvironment in hairy cell leukemia treatment: Facts and perspectives. Front Oncol. (2023) 13:1122699. doi: 10.3389/fonc.2023.1122699

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 116

  LeeS-YKooI-SHwangHJLeeDW. In Vitro three-dimensional (3D) cell culture tools for spheroid and organoid models. SLAS Discov. (2023) 28:119–37. doi: 10.1016/j.slasd.2023.03.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 117

  AbuwatfaWHPittWGHusseiniGA. Scaffold-based 3D cell culture models in cancer research. J BioMed Sci. (2024) 31:7. doi: 10.1186/s12929-024-00994-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 118

  KennyHADoganSZillhardtMK. MitraAYamadaSDKrauszTet al. Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. In: StackMSFishmanDA, editors. Ovarian Cancer. Springer US, Boston, MA (2009). p. 335–51. doi: 10.1007/978-0-387-98094-2_16

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 119

  ModiUMakwanaPVasitaR. Molecular insights of metastasis and cancer progression derived using 3D cancer spheroid co-culture in vitro platform. Crit Rev Oncology/Hematol. (2021) 168:103511. doi: 10.1016/j.critrevonc.2021.103511

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 120

  ScielzoCGhiaP. Modeling the leukemia microenvironment in vitro. Front Oncol. (2020) 10:607608. doi: 10.3389/fonc.2020.607608

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 121

  BarozziDScielzoC. Emerging strategies in 3D culture models for hematological cancers. HemaSphere. (2023) 7:e932. doi: 10.1097/HS9.0000000000000932

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 122

  MattiodaCVoenaCCiardelliGMattuC. In vitro 3D models of hematological Malignancies: current trends and the road ahead? Cells. (2025) 14:38. doi: 10.3390/cells14010038

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 123

  AlhattabDMIsaioglouIAlshehriSKhanZNSusaptoHHLiYet al. Fabrication of a three-dimensional bone marrow niche-like acute myeloid Leukemia disease model by an automated and controlled process using a robotic multicellular bioprinting system. Biomater Res. (2023) 27:111. doi: 10.1186/s40824-023-00457-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 124

  BarbaglioFBelloniDScarfòLSbranaFVPonzoniMBongiovanniLet al. Three-dimensional co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents. hematol. (2020) 106:2334–44. doi: 10.3324/haematol.2020.248112

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 125

  BarozziDScagnoliFBarbaglioFBelloniDRibezziDFarèSet al. Dynamic stimulation promotes functional tissue-like organization of a 3D human lymphoid microenvironment model in vitro. Cell Rep Methods. (2025) 5:101105. doi: 10.1016/j.crmeth.2025.101105

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 126

  IlicJKoelblCSimonFWußmannMEbertRTrivanovicDet al. Liquid overlay and collagen-based three-dimensional models for in vitro investigation of multiple myeloma. Tissue Eng Part C Methods. (2024) 30:193–205. doi: 10.1089/ten.TEC.2023.0374

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 127

  LuanpitpongSJananMPoohadsuanJRodboonNSamartPRungarunlertSet al. A high-throughput, three-dimensional multiple myeloma model recapitulating tumor-stroma interactions for CAR-immune cell-mediated cytotoxicity assay. Immunotargets Ther. (2025) 14:321–38. doi: 10.2147/ITT.S503984

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 128

  FoxallRNarangPGlaysherBHubETealEColesMCet al. Developing a 3D B cell lymphoma culture system to model antibody therapy. Front Immunol. (2021) 11:605231. doi: 10.3389/fimmu.2020.605231

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 129

  CeccatoJPiazzaMPizziMManniSPiazzaFCaputoIet al. A bone-based 3D scaffold as an in-vitro model of microenvironment–DLBCL lymphoma cell interaction. Front Oncol. (2022) 12:947823. doi: 10.3389/fonc.2022.947823

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 130

  WuDWangZLiJSongYPerezMEMWangZet al. A 3D-bioprinted multiple myeloma model. Adv Healthc Mater. (2022) 11:e2100884. doi: 10.1002/adhm.202100884

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 131

  FerrariniMSteimbergNBoniottiJBerenziABelloniDMazzoleniGet al. 3D-dynamic culture models of multiple myeloma. In: KoledovaZ, editor. 3D Cell Culture. Methods in Molecular Biology. Springer New York, New York, NY (2017). p. 177–90. doi: 10.1007/978-1-4939-7021-6_13

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 132

  JakubikovaJCholujovaDHideshimaTGronesovaPSoltysovaAHaradaTet al. A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget. (2016) 7:77326–41. doi: 10.18632/oncotarget.12643

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 133

  RashadHMInsuastiGAlmeida-PoradaGRodriguezC. Abstract 184: Multiple Myeloma 3D model: A platform for testing drug effects on myeloma in conjunction with the bone marrow niche. Cancer Res. (2023) 83:184–4. doi: 10.1158/1538-7445.AM2023-184

  • CrossRef
  • Google Scholar

• 134

  LindacherJHartebrodtADingfelderJLukasPWürthnerLVölklSet al. 3D Tumor microenvironment interaction reveals AP-1 complex regulation and contact-mediated reprogramming of bone marrow stromal cells in chronic lymphocytic leukemia. Hemasphere. (2025) 9:e70199. doi: 10.1002/hem3.70199

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 135

  HaselagerMVvan DrielBFPerelaerEde RooijDLashgariDLoosRet al. In vitro 3D spheroid culture system displays sustained T cell-dependent CLL proliferation and survival. Hemasphere. (2023) 7:e938. doi: 10.1097/HS9.0000000000000938

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 136

  JouybarMMikulaAMZuidmeerNKonijnTde JongeAVRoestHPet al. Lymphoma-on-chip model reveals that lymph node stromal cells promote diffuse large B-cell lymphoma survival and migration. Mater Today Bio. (2025) 31:101544. doi: 10.1016/j.mtbio.2025.101544

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 137

  Duś-SzachniewiczKGdesz-BirulaKRymkiewiczG. Development and characterization of 3D hybrid spheroids for the investigation of the crosstalk between B-cell non-hodgkin lymphomas and mesenchymal stromal cells. Onco Targets Ther. (2022) 15:683–97. doi: 10.2147/OTT.S363994

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 138

  ChalkleyASLopezMTMysiorMMBrinkMCKellySSimpsonJC. Harnessing 3D cell models and high-resolution imaging to unveil the mechanisms of nanoparticle-mediated drug delivery. Front Bioeng Biotechnol. (2025) 13:1606573. doi: 10.3389/fbioe.2025.1606573

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 139

  AlmeriaCWeissRKeckMWeberVKasperCEggerD. Dynamic cultivation of human mesenchymal stem/stromal cells for the production of extracellular vesicles in a 3D bioreactor system. Biotechnol Lett. (2024) 46:279–93. doi: 10.1007/s10529-024-03465-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 140

  WolfP. The nature and significance of platelet products in human plasma. Br J Haematol. (1967) 13:269–88. doi: 10.1111/j.1365-2141.1967.tb08741.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 141

  CiardielloCLeoneALanutiPRocaMSMocciaTMinciacchiVRet al. Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation. J Exp Clin Cancer Res. (2019) 38:317. doi: 10.1186/s13046-019-1317-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 142

  CrescitelliRLässerCLötvallJ. Isolation and characterization of extracellular vesicle subpopulations from tissues. Nat Protoc. (2021) 16:1548–80. doi: 10.1038/s41596-020-00466-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 143

  HefleyBSShresthaPVasiniBSharmaPKaramichosD. Characterizing extracellular vesicles from biological fluids. J Vis Exp. (2025) 196:67699. doi: 10.3791/67699

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 144

  ForteDPellegrinoRMFalvoPGarcia-GonzalezPAlabedHBRMaltoniFet al. Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemia. Nat Commun. (2024) 15:10878. doi: 10.1038/s41467-024-55231-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 145

  Di FeboRSaeedZSerafiniFBroccoDD’AscanioFPizziADet al. Diagnostic and prognostic roles of endothelial- and platelet-derived extracellular vesicles in cardiovascular diseases. J Transl Med. (2025) 23:553. doi: 10.1186/s12967-025-06522-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 146

  WelshJAGoberdhanDCIO’DriscollLBuzasEIBlenkironCBussolatiBet al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. (2024) 13:e12404. doi: 10.1002/jev2.12404

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 147

  KowalJTkachMThéryC. Biogenesis and secretion of exosomes. Curr Opin Cell Biol. (2014) 29:116–25. doi: 10.1016/j.ceb.2014.05.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 148

  ClancyJWSchmidtmannMD’Souza-SchoreyC. The ins and outs of microvesicles. FASEB Bioadv. (2021) 3:399–406. doi: 10.1096/fba.2020-00127

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 149

  BattistelliMFalcieriE. Apoptotic bodies: particular extracellular vesicles involved in intercellular communication. Biol (Basel). (2020) 9:21. doi: 10.3390/biology9010021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 150

  LeeS-SWonJ-HLimGJHanJLeeJYChoK-Oet al. A novel population of extracellular vesicles smaller than exosomes promotes cell proliferation. Cell Commun Signal. (2019) 17:95. doi: 10.1186/s12964-019-0401-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 151

  YuLShiHGaoTXuWQianHJiangJet al. Exomeres and supermeres: Current advances and perspectives. Bioact Mater. (2025) 50:322–43. doi: 10.1016/j.bioactmat.2025.04.012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 152

  FriendCMarovitzWHenieGHenieWTsueiDHirschhornKet al. Observations on cell lines derived from a patient with Hodgkin’s disease. Cancer Res. (1978) 38:2581–91.

  • Pubmed Abstract
  • Google Scholar

• 153

  van BlitterswijkWJEmmelotPHilkmannHAHilgersJFeltkampCA. Rigid plasma-membrane-derived vesicles, enriched in tumor-associated surface antigens (MLr), occurring in the ascites fluid of a murine leukemia (GRSL). Int J Cancer. (1979) 23:62–70. doi: 10.1002/ijc.2910230112

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 154

  KönigLKasimir-BauerSBittnerA-KHoffmannOWagnerBSantos ManvailerLFet al. Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy. Oncoimmunology. (2017) 7:e1376153. doi: 10.1080/2162402X.2017.1376153

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 155

  KhalifeJSanchezJFPichiorriF. Extracellular vesicles in hematological Malignancies: from biomarkers to therapeutic tools. Diagn (Basel). (2020) 10:1065. doi: 10.3390/diagnostics10121065

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 156

  AteeqMBroadwinMSellkeFWAbidMR. Extracellular vesicles’ Role in angiogenesis and altering angiogenic signaling. Med Sci (Basel). (2024) 12:4. doi: 10.3390/medsci12010004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 157

  YeZChenWLiGHuangJLeiJ. Tissue-derived extracellular vesicles in cancer progression: mechanisms, roles, and potential applications. Cancer Metastasis Rev. (2024) 43:575–95. doi: 10.1007/s10555-023-10147-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 158

  SemeradtovaALiegertovaMHermaRCapkovaMBrignoleCDel ZottoG. Extracellular vesicles in cancer´s communication: messages we can read and how to answer. Mol Cancer. (2025) 24:86. doi: 10.1186/s12943-025-02282-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 159

  RaposoGNijmanHWStoorvogelWLiejendekkerRHardingCVMeliefCJet al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. (1996) 183:1161–72. doi: 10.1084/jem.183.3.1161

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 160

  KuangLWuLLiY. Extracellular vesicles in tumor immunity: mechanisms and novel insights. Mol Cancer. (2025) 24:45. doi: 10.1186/s12943-025-02233-w

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 161

  OlejarzWDominiakAŻołnierzakAKubiak-TomaszewskaGLorencT. Tumor-derived exosomes in immunosuppression and immunotherapy. J Immunol Res. (2020) 2020:6272498. doi: 10.1155/2020/6272498

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 162

  HansenHPEngelsHDamsMPaes LemeAFPaulettiBASimhadriVLet al. Protrusion-guided extracellular vesicles mediate CD30 trans-signaling in the microenvironment of Hodgkin’s lymphoma. J Pathol. (2014) 232:405–14. doi: 10.1002/path.4306

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 163

  DavidJDominguezCHamiltonDPalenaC. The IL-8/IL-8R axis: A double agent in tumor immune resistance. Vaccines. (2016) 4:22. doi: 10.3390/vaccines4030022

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 164

  TosettiFVenèRCamodecaCNutiERosselloAD’ArrigoCet al. Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells. Oncoimmunology. (2018) 7:e1421889. doi: 10.1080/2162402X.2017.1421889

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 165

  Manček-KeberMLainščekDBenčinaMChenJGRomihRHunterZRet al. Extracellular vesicle–mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling. Blood. (2018) 131:1720–9. doi: 10.1182/blood-2017-09-805499

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 166

  JiménezCAlonso-ÁlvarezSAlcocebaMOrdóñezGRGarcía-ÁlvarezMPrieto-CondeMIet al. From Waldenström’s macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation. Blood Cancer J. (2017) 7:e591. doi: 10.1038/bcj.2017.72

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 167

  LiuWZhuMWangHWangWLuY. Diffuse large B cell lymphoma-derived extracellular vesicles educate macrophages to promote tumors progression by increasing PGC-1β. Scand J Immunol. (2020) 91:e12841. doi: 10.1111/sji.12841

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 168

  ZhuMLiuWWangHWangWLiuNLuY. NSE from diffuse large B-cell lymphoma cells regulates macrophage polarization. CMAR. (2019) 11:4577–95. doi: 10.2147/CMAR.S203010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 169

  ShaoRLiuCXueRDengXLiuLSongCet al. Tumor-derived exosomal ENO2 modulates polarization of tumor-associated macrophages through reprogramming glycolysis to promote progression of diffuse large B-cell lymphoma. Int J Biol Sci. (2024) 20:848–63. doi: 10.7150/ijbs.91154

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 170

  LouXFuJZhaoXZhuansunXRongCSunMet al. MiR-7e-5p downregulation promotes transformation of low-grade follicular lymphoma to aggressive lymphoma by modulating an immunosuppressive stroma through the upregulation of FasL in M1 macrophages. J Exp Clin Cancer Res. (2020) 39:237. doi: 10.1186/s13046-020-01747-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 171

  ZareNHaghjooy JavanmardSHMehrzadVEskandariNAndalibAR. Effect of plasma-derived exosomes of refractory/relapsed or responsive patients with diffuse large B-cell lymphoma on natural killer cells functions. Cell J. (2020) 22:40–54. doi: 10.22074/cellj.2020.6550

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 172

  ChenZYouLWangLHuangXLiuHWeiJYet al. Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo. J Exp Clin Cancer Res. (2018) 37:190. doi: 10.1186/s13046-018-0863-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 173

  CaoDCaoXJiangYXuJZhengYKangDet al. Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B-cell lymphoma. Hematol Oncol. (2022) 40:172–80. doi: 10.1002/hon.2956

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 174

  WylieCRowanRMalinovaDCrawfordL. Extracellular vesicles in multiple myeloma: pathogenesis and therapeutic application. FEBS J. (2025) 292:4979–91. doi: 10.1111/febs.70093

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 175

  SaltarellaILamanuzziAApollonioBDesantisVBartoliGVaccaAet al. Role of extracellular vesicle-based cell-to-cell communication in multiple myeloma progression. Cells. (2021) 10:3185. doi: 10.3390/cells10113185

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 176

  VulpisECecereFMolfettaRSorianiAFiondaCPeruzziGet al. Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis. Oncoimmunology. (2017) 6:e1279372. doi: 10.1080/2162402X.2017.1279372

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 177

  AllegraADi GioacchinoMTonacciAPetrarcaCMusolinoCGangemiS. Multiple myeloma cell-derived exosomes: implications on tumorigenesis, diagnosis, prognosis and therapeutic strategies. Cells. (2021) 10:2865. doi: 10.3390/cells10112865

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 178

  MatchettECKornbluthJ. Extracellular vesicles derived from immortalized human natural killer cell line NK3.3 as a novel therapeutic for multiple myeloma. Front Immunol. (2023) 14:1265101. doi: 10.3389/fimmu.2023.1265101

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 179

  LeeJYRyuDLimSWRyuKJChoiMEYoonSEet al. Exosomal miR-1305 in the oncogenic activity of hypoxic multiple myeloma cells: a biomarker for predicting prognosis. J Cancer. (2021) 12:2825–34. doi: 10.7150/jca.55553

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 180

  SonciniDMarimpietriDLadisaFLaiFAiroldiIGramignoliRet al. Bone marrow-derived extracellular vesicles from multiple myeloma patients promote adaptive immune dysfunction via HLA-G, PD-1, and PD-L1. Front Immunol. (2025) 16:1640168. doi: 10.3389/fimmu.2025.1640168

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 181

  HagiwaraSRiMEbinaTMarumoYNakamuraTHiradeKet al. Immunosuppressive effects of multiple myeloma-derived extracellular vesicles through T cell exhaustion. Cancer Sci. (2025) 116:1861–70. doi: 10.1111/cas.70099

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 182

  ShaoQDengLLiuHLiuZChenJJiangFet al. Involvement of MM cell-derived exosomes in T lymphocytes immune responses. Oncol Lett. (2020) 20:31. doi: 10.3892/ol.2020.11892

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 183

  MorandiFMarimpietriDHorensteinALBolzoniMToscaniDCostaFet al. Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD. Oncoimmunology. (2018) 7:e1458809. doi: 10.1080/2162402X.2018.1458809

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 184

  WangJDe VeirmanKDe BeuleNMaesKDe BruyneEVan ValckenborghEet al. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells. Oncotarget. (2015) 6:43992–4004. doi: 10.18632/oncotarget.6083

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 185

  LombardiEAlmanzaGKowalKValvasoriMAgostiniFVicinanzaCet al. miR-335-laden B cell-derived extracellular vesicles promote SOX4-dependent apoptosis in human multiple myeloma cells. J Pers Med. (2021) 11:1240. doi: 10.3390/jpm11121240

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 186

  BoysenJNelsonMMagzoubGMaitiGPSinhaSGoswamiMet al. Dynamics of microvesicle generation in B-cell chronic lymphocytic leukemia: implication in disease progression. Leukemia. (2017) 31:350–60. doi: 10.1038/leu.2016.217

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 187

  YehY-YOzerHGLehmanAMMaddocksKYuLJohnsonAJet al. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood. (2015) 125:3297–305. doi: 10.1182/blood-2014-12-618470

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 188

  De LucaLD’ArenaGSimeonVTrinoSLaurenzanaICaivanoAet al. Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia. Leuk Lymphoma. (2017) 58:1424–32. doi: 10.1080/10428194.2016.1243790

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 189

  GhoshAKSecretoCRKnoxTRDingWMukhopadhyayDKayNE. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood. (2010) 115:1755–64. doi: 10.1182/blood-2009-09-242719

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 190

  CaivanoALaurenzanaIDe LucaLLa RoccaFSimeonVTrinoSet al. High serum levels of extracellular vesicles expressing Malignancy-related markers are released in patients with various types of hematological neoplastic disorders. Tumor Biol. (2015) 36:9739–52. doi: 10.1007/s13277-015-3741-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 191

  PaggettiJHaderkFSeiffertMJanjiBDistlerUAmmerlaanWet al. Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood. (2015) 126:1106–17. doi: 10.1182/blood-2014-12-618025

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 192

  MandalRBeckerSStrebhardtK. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. Oncogene. (2016) 35:2547–61. doi: 10.1038/onc.2015.329

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 193

  NabetBYQiuYShabasonJEWuTJYoonTKimBCet al. Exosome RNA unshielding couples stromal activation to pattern recognition receptor signaling in cancer. Cell. (2017) 170:352–366.e13. doi: 10.1016/j.cell.2017.06.031

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 194

  SmallwoodDTApollonioBWillimottSLezinaLAlharthiAAmbroseARet al. Extracellular vesicles released by CD40/IL-4-stimulated CLL cells confer altered functional properties to CD4+ T cells. Blood. (2016) 128:542–52. doi: 10.1182/blood-2015-11-682377

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 195

  GargiuloEViryEMorandePELargeotAGonderSXianFet al. Extracellular vesicle secretion by leukemia cells in vivo promotes CLL progression by hampering antitumor T-cell responses. Blood Cancer Discov. (2023) 4:54–77. doi: 10.1158/2643-3230.BCD-22-0029

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 196

  HedlundMNagaevaOKarglDBaranovVMincheva-NilssonL. Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PloS One. (2011) 6:e16899. doi: 10.1371/journal.pone.0016899

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 197

  VeleticIHarrisDMRozovskiUBertilaccioMTSCalinGATakahashiKet al. CLL cell-derived exosomes alter the immune and hematopoietic systems. Leukemia. (2025) 39:1380–94. doi: 10.1038/s41375-025-02590-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 198

  IkhlefLRattiNDurandSFormentoRDaveratHBoutaudMet al. Extracellular vesicles from type-2 macrophages increase the survival of chronic lymphocytic leukemia cells ex vivo. Cancer Gene Ther. (2024) 31:1164–76. doi: 10.1038/s41417-024-00802-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 199

  DuboisNVan MorckhovenDTillemanLVan NieuwerburghFBronDLagneauxLet al. Extracellular vesicles from chronic lymphocytic leukemia cells promote leukemia aggressiveness by inducing the differentiation of monocytes into nurse-like cells via an RNA-dependent mechanism. Hemasphere. (2025) 9:e70068. doi: 10.1002/hem3.70068

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 200

  FaisSO’DriscollLBorrasFEBuzasECamussiGCappelloFet al. Evidence-based clinical use of nanoscale extracellular vesicles in nanomedicine. ACS Nano. (2016) 10:3886–99. doi: 10.1021/acsnano.5b08015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 201

  ChaudhuriOGuLDarnellMKlumpersDBencherifSAWeaverJCet al. Substrate stress relaxation regulates cell spreading. Nat Commun. (2015) 6:6364. doi: 10.1038/ncomms7365

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 202

  ShimodaMKhokhaR. Metalloproteinases in extracellular vesicles. Biochim Biophys Acta Mol Cell Res. (2017) 1864:1989–2000. doi: 10.1016/j.bbamcr.2017.05.027

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 203

  ShimodaM. Extracellular vesicle-associated MMPs: A modulator of the tissue microenvironment. Adv Clin Chem. (2019) 88:35–66. doi: 10.1016/bs.acc.2018.10.006

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 204

  MasolaVBellinGGambaroGOnistoM. Heparanase: A multitasking protein involved in extracellular matrix (ECM) remodeling and intracellular events. Cells. (2018) 7:236. doi: 10.3390/cells7120236

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 205

  VlodavskyIBarashUNguyenHMYangS-MIlanN. Biology of the heparanase-heparan sulfate axis and its role in disease pathogenesis. Semin Thromb Hemost. (2021) 47:240–53. doi: 10.1055/s-0041-1725066

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 206

  TripathiKBandariSKSandersonRD. Extracellular vesicles released during hypoxia transport heparanase and enhance macrophage migration, endothelial tube formation and cancer cell stemness. Proteoglycan Res. (2023) 1:e1. doi: 10.1002/pgr2.1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 207

  PurushothamanABandariSKLiuJMobleyJABrownEESandersonRD. Fibronectin on the surface of myeloma cell-derived exosomes mediates exosome-cell interactions. J Biol Chem. (2016) 291:1652–63. doi: 10.1074/jbc.M115.686295

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 208

  WatrinTSeifertMDietrichS. The tumor microenvironment in hairy cell leukemia (HCL) and splenic B cell lymphoma with prominent nucleoli (SBLPN). Leukemia Lymphoma. (2025) 67(1):1–10. doi: 10.1080/10428194.2025.2562951

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 209

  AzizKATillKJZuzelMCawleyJC. Involvement of CD44-hyaluronan interaction in Malignant cell homing and fibronectin synthesis in hairy cell leukemia. Blood. (2000) 96:3161–7. doi: 10.1182/blood.V96.9.3161

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 210

  AzizKATillKJChenHSlupskyJRCampbellFCawleyJCet al. The role of autocrine FGF-2 in the distinctive bone marrow fibrosis of hairy-cell leukemia (HCL). Blood. (2003) 102:1051–6. doi: 10.1182/blood-2002-12-3737

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 211

  GruberGSchwarzmeierJDShehataMHilgarthMBergerR. Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia. Blood. (1999) 94:1077–85. doi: 10.1182/blood.V94.3.1077.415k06_1077_1085

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 212

  KimDBaekJ-H. Macrophages and fibroblasts in cardiac fibrosis: interactions and transformation. Explor Immunol. (2025) 5:1003211. doi: 10.37349/ei.2025.1003211

  • CrossRef
  • Google Scholar

• 213

  AnnaratoneLDe PalmaGBonizziGSapinoABottiGBerrinoEet al. Basic principles of biobanking: from biological samples to precision medicine for patients. Virchows Arch. (2021) 479:233–46. doi: 10.1007/s00428-021-03151-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 214

  PellicoMRDayJShahMYiBYSaketkooLALoodCet al. Biorepositories for global rare disease research: A narrative review. Curr Rheumatol Rep. (2025) 27:24. doi: 10.1007/s11926-025-01189-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 215

  GarciaMDownsJRussellAWangW. Impact of biobanks on research outcomes in rare diseases: a systematic review. Orphanet J Rare Dis. (2018) 13:202. doi: 10.1186/s13023-018-0942-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 216

  López-GuerreroJAValés-GómezMBorrásFEFalcón-PérezJMVicentMJYáñez-MóM. Standardizing the preanalytical reporting of biospecimens to improve reproducibility in extracellular vesicle research - A GEIVEX study. J Extracell Biol. (2023) 2:e76. doi: 10.1002/jex2.76

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 217

  CoumansFAWBrissonARBuzasEIDignat-GeorgeFDreesEEEEl-AndaloussiSet al. Methodological guidelines to study extracellular vesicles. Circ Res. (2017) 120:1632–48. doi: 10.1161/CIRCRESAHA.117.309417

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 218

  LucienFGustafsonDLenassiMLiBTeskeJJBoilardEet al. MIBlood-EV: Minimal information to enhance the quality and reproducibility of blood extracellular vesicle research. J Extracell Vesicles. (2023) 12:e12385. doi: 10.1002/jev2.12385

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 219

  YuanaYBertinaRMOsantoS. Pre-analytical and analytical issues in the analysis of blood microparticles. Thromb Hemost. (2011) 105:396–408. doi: 10.1160/TH10-09-0595

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 220

  LiguoriGLKisslingerA. Standardization and reproducibility in EV research: the support of a Quality Management System. In: Advances in biomembranes and lipid self-assembly. Amsterdam: Elsevier (2021). p. 175–206. doi: 10.1016/bs.abl.2020.05.005

  • CrossRef
  • Google Scholar

• 221

  GargiuloEMorandePELargeotAMoussayEPaggettiJ. Diagnostic and therapeutic potential of extracellular vesicles in B-cell Malignancies. Front Oncol. (2020) 10:580874. doi: 10.3389/fonc.2020.580874

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 222

  MizenkoRRFeaverMBozkurtBTLoweNNguyenBHuangK-Wet al. A critical systematic review of extracellular vesicle clinical trials. J Extracell Vesicles. (2024) 13:e12510. doi: 10.1002/jev2.12510

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 223

  Van MorckhovenDDuboisNBronDMeulemanNLagneauxLStamatopoulosB. Extracellular vesicles in hematological Malignancies: EV-dence for reshaping the tumoral microenvironment. Front Immunol. (2023) 14:1265969. doi: 10.3389/fimmu.2023.1265969

  • Pubmed Abstract
  • CrossRef
  • Google Scholar